UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


(Mark One)


x    Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 Forfor the Quarterly Period Ended September 30, 2017


March 31, 2023

o    Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Commission File Number: 1-8351


CHEMED CORPORATION

(Exact name of registrant as specified in its charter)


Delaware

31-0791746

Delaware

31-0791746

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

255 E. Fifth Street, Suite 2600, Cincinnati, Ohio

45202

(Address of principal executive offices)

(Zip code)

(513) 762-6690

(Registrant’s telephone number, including area code)


(513) 762-6690
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Yes  

x

No  

o


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes

No

Yes  

x

No  

o


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Large Accelerated Filer

x

Accelerated Filer

o

Non-accelerated Filer

o

Emerging growth company

Smaller Reporting Company

o

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act


o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

Yes  

o

No  

x


Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Securities registered pursuant to Section 12(b) of the Act:


Class

Amount

Date

Title of Each Class

Trading Symbol

Name of Each Exchange

on which Registered

Amount

Date

Capital Stock $1 Par Value

CHE

15,966,003

New York Stock Exchange

15,019,778 Shares

March 31, 2023

September 30, 2017




-1-

-1-




CHEMED CORPORATION AND

SUBSIDIARY COMPANIES

Index




Index

Page No.

Page No.

PART I. FINANCIAL INFORMATION:

Item 1. Financial Statements

Unaudited Consolidated Balance Sheets -

2022

3

Unaudited Consolidated Statements of Income -

2022

4

Unaudited Consolidated Statements of Cash Flows -

2022

5

Unaudited Consolidated Statements of Changes in Stockholders’ Equity-

Three months ended March 31, 2023 and 2022

6

Notes to Unaudited Consolidated Financial Statements

6

7

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

16

20

Item 3. Quantitative and Qualitative Disclosures about Market Risk

34

30

Item 4. Controls and Procedures

34

30

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

34

30

34

30

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

35

31

Item 3. Defaults Upon Senior Securities

35

31

Item 4. Mine Safety Disclosures

35

31

Item 5. Other Information

35

31

Item 6. Exhibits

36

32

EX – 101.INS101

EX – 101.SCH104

EX – 101.CAL

SIGNATURES

EX – 101.DEF
EX – 101.LAB
EX – 101.PRE

33


-2-

-2-



PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

March 31, 2023

December 31, 2022

ASSETS

Current assets

Cash and cash equivalents

$

58,054 

$

74,126 

Accounts receivable

153,816 

139,408 

Inventories

10,663 

10,272 

Prepaid income taxes

10,633 

18,515 

Prepaid expenses

29,055 

30,291 

Total current assets

262,221 

272,612 

Investments of deferred compensation plans

97,436 

93,196 

Properties and equipment, at cost, less accumulated depreciation of $338,416 (2022- $335,920)

204,164 

199,714 

Lease right of use asset

131,219 

135,662 

Identifiable intangible assets less accumulated amortization of $70,229 (2022 - $67,716)

97,348 

99,726 

Goodwill

581,286 

581,295 

Other assets

57,511 

59,807 

Total Assets

$

1,431,185 

$

1,442,012 

LIABILITIES

Current liabilities

Accounts payable

$

40,279 

$

41,884 

Current portion of long-term debt

5,000 

5,000 

Income taxes

11,223 

-

Accrued insurance

63,150 

58,515 

Accrued compensation

50,152 

87,350 

Accrued legal

6,061 

4,456 

Short-term lease liability

38,291 

38,996 

Other current liabilities

69,304 

61,004 

Total current liabilities

283,460 

297,205 

Deferred income taxes

35,418 

38,613 

Long-term debt

16,250 

92,500 

Deferred compensation liabilities

97,285 

92,330 

Long-term lease liability

106,212 

110,513 

Other liabilities

12,507 

12,136 

Total Liabilities

551,132 

643,297 

Commitments and contingencies (Note 10)

 

 

STOCKHOLDERS' EQUITY

Capital stock - authorized 80,000,000 shares $1 par; issued 36,884,382 shares (2022 - 36,795,792 shares)

36,884 

36,796 

Paid-in capital

1,186,119 

1,149,899 

Retained earnings

2,246,354 

2,197,918 

Treasury stock - 21,927,705 shares (2022 - 21,920,993 shares)

(2,591,588)

(2,588,145)

Deferred compensation payable in Company stock

2,284 

2,247 

Total Stockholders' Equity

880,053 

798,715 

Total Liabilities and Stockholders' Equity

$

1,431,185 

$

1,442,012 

See Accompanying Notes to Unaudited Consolidated Financial Statements.

PART I. FINANCIAL INFORMATION 
Item 1. Financial Statements 
CHEMED CORPORATION AND SUBSIDIARY COMPANIES 
UNAUDITED CONSOLIDATED BALANCE SHEETS
 
(in thousands, except share and per share data) 
       
       
       
  September 30, 2017  December 31, 2016 
ASSETS      
Current assets      
Cash and cash equivalents $18,871  $15,310 
Accounts receivable less allowances of $14,997 (2016 - $14,236)  91,483   132,021 
Inventories  5,658   5,755 
Prepaid income taxes  3,621   3,709 
Prepaid expenses  15,678   13,105 
Total current assets  135,311   169,900 
Investments of deferred compensation plans  60,445   54,389 
Properties and equipment, at cost, less accumulated depreciation of $227,036 (2016 - $211,290)  143,148   121,302 
Identifiable intangible assets less accumulated amortization of $32,862 (2016 - $33,225)  54,793   55,065 
Goodwill  473,024   472,366 
Deferred income taxes  21,893   8 
Other assets  6,845   7,029 
Total Assets $895,459  $880,059 
         
LIABILITIES        
Current liabilities        
Accounts payable $34,752  $39,586 
Current portion of long-term debt  10,000   8,750 
Income taxes  12,349   - 
Accrued insurance  44,584   47,960 
Accrued compensation  53,857   53,979 
Accrued legal  91,450   1,805 
Other current liabilities  22,382   19,752 
Total current liabilities  269,374   171,832 
Deferred income taxes  -   14,291 
Long-term debt  72,500   100,000 
Deferred compensation liabilities  59,389   54,288 
Other liabilities  16,494   15,549 
Total Liabilities  417,757   355,960 
Commitments and contingencies (Note 11)        
STOCKHOLDERS' EQUITY        
Capital stock - authorized 80,000,000 shares $1 par; issued 34,513,535 shares (2016 - 34,270,104 shares)  34,514   34,270 
Paid-in capital  668,573   639,703 
Retained earnings  988,895   958,149 
Treasury stock - 18,632,867 shares (2016 - 18,083,527)  (1,216,509)  (1,110,536)
Deferred compensation payable in Company stock  2,229   2,513 
Total Stockholders' Equity  477,702   524,099 
Total Liabilities and Stockholders' Equity $895,459  $880,059 
  
See accompanying notes to unaudited consolidated financial statements. 


-3-

-3-



CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

Three Months Ended March 31,

2023

2022

Service revenues and sales

$

560,157 

$

530,549 

Cost of services provided and goods sold (excluding depreciation)

370,705 

336,552 

Selling, general and administrative expenses

100,095 

89,954 

Depreciation

12,286 

12,138 

Amortization

2,513 

2,518 

Other operating expense

1,739 

13 

Total costs and expenses

487,338 

441,175 

Income from operations

72,819 

89,374 

Interest expense

(1,551)

(810)

Other expense - net

(103)

(3,862)

Income before income taxes

71,165 

84,702 

Income taxes

(17,044)

(20,533)

Net income

$

54,121 

$

64,169 

Earnings Per Share:

Net income

$

3.62 

$

4.28 

Average number of shares outstanding

14,966 

14,986 

Diluted Earnings Per Share:

Net income

$

3.58 

$

4.22 

Average number of shares outstanding

15,110 

15,192 

Cash Dividends Per Share

$

0.38 

$

0.36 

See Accompanying Notes to Unaudited Consolidated Financial Statements.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES 
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
 
(in thousands, except per share data) 
             
             
             
  Three Months Ended September 30,  Nine Months Ended September 30, 
  2017  2016  2017  2016 
Service revenues and sales $417,444  $392,607  $1,238,367  $1,173,405 
Cost of services provided and goods sold (excluding depreciation)  288,047   281,658   859,039   836,348 
Selling, general and administrative expenses  66,919   59,373   205,031   181,046 
Depreciation  8,819   8,614   26,545   25,619 
Amortization  33   91   111   274 
Other operating expenses/(income)  (371)  -   91,138   4,491 
Total costs and expenses  363,447   349,736   1,181,864   1,047,778 
Income from operations  53,997   42,871   56,503   125,627 
Interest expense  (1,048)  (1,018)  (3,164)  (2,831)
Other income - net  1,323   1,640   5,439   1,933 
Income before income taxes  54,272   43,493   58,778   124,729 
Income taxes  (18,835)  (16,664)  (15,153)  (48,175)
Net income $35,437  $26,829  $43,625  $76,554 
                 
Earnings Per Share                
Net income $2.22  $1.66  $2.72  $4.66 
Average number of shares outstanding  15,976   16,166   16,068   16,443 
                 
Diluted Earnings Per Share                
Net income $2.13  $1.62  $2.60  $4.54 
Average number of shares outstanding  16,676   16,559   16,763   16,851 
                 
Cash Dividends Per Share $0.28  $0.26  $0.80  $0.74 
                 
See accompanying notes to unaudited consolidated financial statements. 


-4-

-4-



CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Three Months Ended March 31,

2023

2022

Cash Flows from Operating Activities

Net income

$

54,121 

$

64,169 

Adjustments to reconcile net income to net cash provided

by operating activities:

Depreciation and amortization

14,799 

14,656 

Stock option expense

8,482 

7,451 

Benefit for deferred income taxes

(3,195)

(4,047)

Noncash long-term incentive compensation

2,024 

1,185 

Amortization of debt issuance costs

95 

76 

Changes in operating assets and liabilities:

(Increase)/decrease in accounts receivable

(14,318)

19,610 

Increase in inventories

(391)

(431)

Decrease in prepaid expenses

1,236 

3,099 

Decrease in accounts payable and other current liabilities

(24,109)

(30,332)

Change in current income taxes

19,118 

23,530 

Net change in lease assets and liabilities

(632)

743 

Increase in other assets

(2,173)

(1,562)

Increase in other liabilities

5,313 

2,958 

Other sources/(uses)

122 

(15)

Net cash provided by operating activities

60,492 

101,090 

Cash Flows from Investing Activities

Capital expenditures

(17,020)

(12,649)

Proceeds from sale of fixed assets

146 

485 

Business combinations, net of cash acquired

-

(1,650)

Other uses

(139)

(134)

Net cash used by investing activities

(17,013)

(13,948)

Cash Flows from Financing Activities

Payments on long-term debt

(76,250)

-

Proceeds from exercise of stock options

25,680 

7,692 

Dividends paid

(5,685)

(5,322)

Capital stock surrendered to pay taxes on stock-based compensation

(3,166)

(4,893)

Payments on revolving line of credit

-

(86,500)

Purchases of treasury stock

-

(27,794)

Proceeds from revolving line of credit

-

21,500 

Change in cash overdrafts payable

-

(7,051)

Other (uses)/sources

(130)

491 

Net cash used by financing activities

(59,551)

(101,877)

Decrease in Cash and Cash Equivalents

(16,072)

(14,735)

Cash and cash equivalents at beginning of period

74,126 

32,895 

Cash and cash equivalents at end of period

$

58,054 

$

18,160 

See Accompanying Notes to Unaudited Consolidated Financial Statements.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES 
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
 
(in thousands) 
    
  Nine Months Ended September 30, 
  2017  2016 
Cash Flows from Operating Activities      
Net income $43,625  $76,554 
Adjustments to reconcile net income to net cash provided        
by operating activities:        
Depreciation and amortization  26,656   25,893 
Provision for uncollectible accounts receivable  12,953   12,132 
Stock option expense  7,738   6,259 
Benefit for deferred income taxes  (36,175)  (5,530)
Potential litigation settlement  90,000   - 
Noncash early retirement expense  -   1,747 
Amortization of restricted stock awards  933   1,415 
Noncash directors' compensation  766   541 
Noncash long-term incentive compensation  2,888   837 
Amortization of debt issuance costs  387   390 
Changes in operating assets and liabilities:        
Decrease in accounts receivable  27,534   8,061 
Decrease in inventories  97   213 
Increase in prepaid expenses  (2,573)  (1,646)
Increase/(decrease) in accounts payable and other current liabilities  2,448   (5,471)
Increase in income taxes  12,432   8,587 
Increase in other assets  (6,238)  (5,694)
Increase in other liabilities  6,046   6,835 
Excess tax benefit on share-based compensation  -   (2,974)
Other sources  1,472   204 
Net cash provided by operating activities  190,989   128,353 
Cash Flows from Investing Activities        
Capital expenditures  (50,247)  (29,708)
Business combinations  (525)  - 
Other sources/(uses)  116   (114)
Net cash used by investing activities  (50,656)  (29,822)
Cash Flows from Financing Activities        
Payments on revolving line of credit  (203,700)  (85,200)
Proceeds from revolving line of credit  183,700   110,200 
Purchases of treasury stock  (94,640)  (102,313)
Dividends paid  (12,879)  (12,215)
Proceeds from exercise of stock options  11,625   4,625 
Change in cash overdrafts payable  (8,139)  2,092 
Capital stock surrendered to pay taxes on stock-based compensation  (7,637)  (7,051)
Payments on other long-term debt  (6,250)  (5,625)
Excess tax benefit on share-based compensation  -   2,974 
Other sources  1,148   540 
Net cash used by financing activities  (136,772)  (91,973)
Increase in Cash and Cash Equivalents  3,561   6,558 
Cash and cash equivalents at beginning of year  15,310   14,727 
Cash and cash equivalents at end of period $18,871  $21,285 
         
See accompanying notes to unaudited consolidated financial statements. 


-5-

-5-




CHEMED CORPORATION AND SUBSIDIARY COMPANIES

UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except per share data)

For the three months ended March 31, 2023 and 2022:

Deferred

Compensation

Treasury

Payable in

Capital

Paid-in

Retained

Stock-

Company

Stock

Capital

Earnings

at Cost

Stock

Total

Balance at December 31, 2022

36,796 

1,149,899 

2,197,918 

(2,588,145)

2,247 

$

798,715 

Net income

-

-

54,121 

-

-

54,121 

Dividends paid ($0.38 per share)

-

-

(5,685)

-

-

(5,685)

Stock awards and exercise of stock options

88 

36,338 

-

(3,406)

-

33,020 

Purchases of treasury stock

-

-

-

-

-

-

Other

-

(118)

-

(37)

37 

(118)

Balance at March 31, 2023

$

36,884 

$

1,186,119 

$

2,246,354 

$

(2,591,588)

$

2,284 

$

880,053 

Deferred

Compensation

`

Treasury

Payable in

Capital

Paid-in

Retained

Stock-

Company

Stock

Capital

Earnings

at Cost

Stock

Total

Balance at December 31, 2021

36,514 

1,044,341 

1,970,311 

(2,430,094)

2,201 

623,273 

Net income

-

-

64,169 

-

-

64,169 

Dividends paid ($0.36 per share)

-

-

(5,322)

-

-

(5,322)

Stock awards and exercise of stock options

65 

19,603 

-

(8,233)

-

11,435 

Purchases of treasury stock

-

-

-

(27,353)

-

(27,353)

Other

-

504 

-

(36)

35 

503 

Balance at March 31, 2022

$

36,579 

$

1,064,448 

$

2,029,158 

$

(2,465,716)

$

2,236 

$

666,705 

See Accompanying Notes to Unaudited Consolidated Financial Statements.


-6-


CHEMED CORPORATION AND SUBSIDIARY COMPANIES

Notes to Unaudited Consolidated Financial Statements


1.    Basis of Presentation


As used herein, the terms "We," "Company"“We,” “Company” and "Chemed"“Chemed” refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries.


We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X. Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The December 31, 20162022 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP. However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 or any other future period, and we make no representations related thereto. These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related notesNotes included in our Annual Report on Form 10-K for the year ended December 31, 2016.2022.

CLOUD COMPUTING

As of March 31, 2023, Roto-Rooter has no significant capitalized implementation costs related to cloud computing.

VITAS utilizes a human resources system that is considered a cloud computing arrangement. We have capitalized approximately $5.6 million related to implementation of this project which is included in prepaid assets in the accompanying balance sheets. The VITAS human resource system was placed into service in January 2020 and is being amortized over 5.7 years. For the three months ended March 31, 2023 and 2022, $249,000 has been amortized, respectively.

INCOME TAXES

Our effective income tax rate was 23.9% in the first quarter of 2023 compared to 24.2% during the first quarter of 2022. Excess tax benefit on stock options exercised reduced our income tax expenses by $1.7 million and $1.4 million, respectively for the quarters ended March 31, 2023 and 2022.

NON-CASH TRANSACTIONS

Included in the accompanying Consolidated Balance Sheets are $1.7 million and $1.9 million of capitalized property and equipment which were not paid for as of March 31, 2023 and December 31, 2022, respectively. Accrued property and equipment purchases have been excluded from capital expenditures in the accompanying Consolidated Statements of Cash Flow. There are no material non-cash amounts included in interest expense for any period presented.

BUSINESS COMBINATIONS

We account for acquired businesses using the acquisition method of accounting. All assets acquired and liabilities assumed are recorded at their respective fair values at the date of acquisition. The determination of fair value involves estimates and the use of valuation techniques when market value is not readily available. We use various techniques to determine fair value in accordance with accepted valuation models, primarily the income approach. The significant assumptions used in developing fair values include, but are not limited to, revenue growth rates, the amount and timing of future cash flows, discount rates, useful lives, royalty rates and future tax rates. The excess of purchase price over the fair value of assets and liabilities acquired is recorded as goodwill. See Note 17 for discussion of recent acquisitions.

Quarterly amortization of intangible assets is mainly driven by two Roto-Rooter franchise acquisitions completed in 2019. The total purchase price of these acquisitions was $138.0 million. As part of the purchase price allocation, approximately $59.2 million was determined to be the value of reacquired franchise rights which are being amortized over the remaining life of each franchise agreement. The average remaining life on the reacquired franchise agreements was approximately seven years. Quarterly amortization of reacquired franchise rights for these two acquisitions is approximately $2.0 million ($8.1 million annualized through 2026). This contrasts to quarterly franchise fees historically collected from these two franchisees of approximately $470,000 ($1.9 million annualized).

ESTIMATES

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect amounts reported in the consolidated financial statements and


-7-


EARNINGS PER SHARE

accompanying Notes. Actual results could differ from those estimates. Disclosures of after-tax expenses and adjustments are based on estimates of the effective income tax rates for the applicable segments.

2.    Revenue Recognition

In March 2016,May 2014, the FASB issued Accounting Standards Update “ASU No. 2016-09 - Compensation2014-09Stock Compensation” whichRevenue from Contracts with Customers.” The standard and subsequent amendments are intended to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide for more useful information to users through improved disclosure requirements and simplify the preparation of financial statements. The standard is partalso referred to as Accounting Standards Codification No. 606 (“ASC 606”).

VITAS

Service revenue for VITAS is reported at the amount that reflects the ultimate consideration we expect to receive in exchange for providing patient care. These amounts are due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), and include variable consideration for revenue adjustments due to settlements of audits and reviews, as well as certain hospice-specific revenue capitations. Amounts are generally billed monthly or subsequent to patient discharge. Subsequent changes in the transaction price initially recognized are not significant.

Hospice services are provided on a daily basis and the type of service provided is determined based on a physician’s determination of each patient’s specific needs on that given day. Reimbursement rates for hospice services are on a per diem basis regardless of the FASB’s Simplification Initiative.type of service provided or the payor. Reimbursement rates from government programs are established by the appropriate governmental agency and are standard across all hospice providers. Reimbursement rates from health insurers are negotiated with each payor and generally structured to closely mirror the Medicare reimbursement model. The objecttypes of this initiativehospice services provided and associated reimbursement model for each are as follows:

Routine Home Care occurs when a patient receives hospice care in their home, including a nursing home setting.  The routine home care rate is to identify, evaluate,paid for each day that a patient is in a hospice program and improve areas of GAAP. The areas of simplification in this initiative involve several aspectsis not receiving one of the accountingother categories of hospice care.  For Medicare patients, the routine home care rate reflects a two-tiered rate, with a higher rate for share-basedthe first 60 days of a hospice patient’s care and a lower rate for days 61 and after.  In addition, there is a Service Intensity Add-on payment transactions,which covers direct home care visits conducted by a registered nurse or social worker in the last seven days of a hospice patient’s life, reimbursed up to 4 hours per day in 15 minute increments at the continuous home care rate.

General Inpatient Care occurs when a patient requires services in a controlled setting for a short period of time for pain control or symptom management which cannot be managed in other settings.  General inpatient care services must be provided in a Medicare or Medicaid certified hospital or long-term care facility or at a freestanding inpatient hospice facility with the required registered nurse staffing.

Continuous Home Care is provided to patients while at home, including a nursing home setting, during periods of crisis when intensive monitoring and care, primarily nursing care, is required in order to achieve palliation or management of acute medical symptoms.  Continuous home care requires a minimum of 8 hours of care within a 24-hour day, which begins at midnight.  The care must be predominantly nursing care provided by either a registered nurse or licensed nurse practitioner.  While the income tax consequences, classificationpublished Medicare continuous home care rates are daily rates, Medicare pays for continuous home care in 15 minute increments.  This 15 minute rate is calculated by dividing the daily rate by 96.

Respite Care permits a hospice patient to receive services on an inpatient basis for a short period of awardstime in order to provide relief for the patient’s family or other caregivers from the demands of caring for the patient.  A hospice can receive payment for respite care for a given patient for up to five consecutive days at a time, after which respite care is reimbursed at the routine home care rate.

Each level of care represents a separate promise under the contract of care and is provided independently for each patient contingent upon the patient’s specific medical needs as determined by a physician. However, the clinical criteria used to determine a patient’s level of care is consistent across all patients, given that, each patient is subject to the same payor rules and regulations. As a result, we have concluded that each level of care is capable of being distinct and is distinct in the context of the contract. Furthermore, we have determined that each level of care represents a stand ready service provided as a series of either equitydays or liabilities, and classificationhours of patient care. We believe that the performance obligations for each level of care meet criteria to be satisfied over time. VITAS recognizes revenue based on the statementservice output. VITAS believes this to be the most faithful depiction of cash flows.  The guidance was effective for fiscal years beginning after December 15, 2016.  We adopted the applicable provisionstransfer of ASU 2016-09control of services as the patient simultaneously receives and consumes the benefits provided by our performance. Revenue is recognized on a prospective basis.daily or hourly basis for each patient in accordance with the reimbursement model for each type of service. VITAS’ performance obligations relate to contracts with an expected duration of less than one year. Therefore, VITAS has elected to apply the optional exception provided in ASC 606 and

-8-


is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The impactunsatisfied or partially satisfied performance obligations referred to above relate to bereavement services provided to patients’ families for at least 12 months after discharge.

Care is provided to patients regardless of this ASU ontheir ability to pay. Patients who meet our financial statementscriteria for charity care are provided care without charge. There is no revenue or associated accounts receivable in the accompanying Consolidated Financial Statements related to charity care. The cost of providing charity care was $2.0 million for the quarterquarters ended September 30, 2017 wasMarch 31, 2023 and 2022. The cost of charity care is included in cost of services provided and goods sold and is calculated by taking the ratio of charity care days to decrease our income tax expensetotal days of care and multiplying by $1.8 millionthe total cost of care.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance which vary in amount. VITAS also provides service to patients without a reimbursement source and may offer those patients discounts from standard charges. VITAS estimates the transaction price for patients with deductibles and coinsurance, along with those uninsured patients, based on historical experience and current conditions. The estimate of any contractual adjustments, discounts or implicit price concessions reduces the amount of revenue initially recognized. Subsequent changes to the estimate of the transaction price are recorded as adjustments to patient service revenue in the period of change. Subsequent changes that are determined to be the result of an adverse change in the patients’ ability to pay (i.e. change in credit risk) are recorded as bad debt expense. VITAS has no material adjustments related to subsequent changes in the estimate of the transaction price or subsequent changes as the result of excess tax benefits on stockan adverse change in the patient’s ability to pay for any period reported.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. Medicare and Medicaid programs have broad authority to audit and review compliance with such laws and regulations, and impose payment suspensions when merited. Additionally, the contracts we have with commercial health insurance payors provide for retroactive audit and review of claims. Settlement with third party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. The variable consideration is estimated based compensation being recorded on the statementsterms of income. This, combined with the required change in diluted share count, resulted in an increase to basic and diluted earnings per share of $0.11 and $0.09, respectively. The impact of this ASU on our financial statements for the nine months ended September 30, 2017 was to decrease our income tax expense by $8.1 million as the result of excess tax benefits on stock based compensation being recorded on the statements of income. This, combined with the required change in diluted share count, resulted in an increase to basic earnings per share by $0.51 and an increase to diluted earnings per share by $0.46.


INCOME TAXES
The effective tax rate for the three and nine month periods ended September 30, 2017 was 34.7% and 25.8%, respectively.  These rates differpayment agreement, existing correspondence from the US statutory tax rates primarilypayor and our historical settlement activity. These estimates are adjusted in future periods, as the result of the adoption of ASU 2016-09 described above. 

2.   Revenue Recognition

Both the VITAS segment and the Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed.  Generally, this occurs when services are provided or products are shipped.  VITAS recognizes revenue at the estimated realizable amount due from third-party payers.  Medicare paymentsnew information becomes available.

We are subject to certain limitations on Medicare payments for services which are considered variable consideration, as described below.


follows:

Inpatient Cap. If the number of inpatient care days any hospice program provides to Medicare beneficiaries exceeds 20% of the total days of hospice care such program provided to all Medicare patients for an annual period beginning September 28, the days in excess of the 20% figure may be reimbursed only at the routine homecare rate. None of VITAS’ hospice programs exceeded the payment limits on inpatient services during the three months ended March 31, 2023 and 2022.

Medicare Cap. We are also subject to a Medicare annual per-beneficiary cap (“Medicare cap”). Compliance with the Medicare cap is measured in one of two ways based on a provider election. The “streamlined” method compares total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by that Medicare provider number with the product of the per-beneficiary cap amount and the number of Medicare beneficiaries electing hospice care for the first time from that hospice program or programs from September 28 through September 27 of the following year. At March 31, 2023, all our programs except one are using the “streamlined” method.

The “proportional” method compares the total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by the Medicare provider number between September 28 and September 27 of the following year with the product of the per beneficiary cap amount and a pro-rated number of Medicare beneficiaries receiving hospice services from that program during the same period. The pro-rated number of Medicare beneficiaries is calculated based on the ratio of days the beneficiary received hospice services during the measurement period to the total number of days the beneficiary received hospice services.

We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether theyrevenues are likely to exceed the annual per-beneficiary Medicare cap (“Medicare cap”).cap. Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective actionactions, which include changes to influence the patient mix or to increaseand increased patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the periodgovernment fiscal year that will require repayment to the Federal government under the Medicare cap and record an adjustment to revenue of an amount equal to a ratable portion of our best estimate for the amount as a reduction to patient revenue.year.


-9-


In 2013, the U.S. government implemented automatic budget reductions of 2.0% for all government payees, including hospice benefits paid under the Medicare program. In 2015, CMSCenters for Medicare and Medicaid Services (“CMS”) determined that the Medicare cap should be calculated “as if” sequestration did not occur. As a result of this decision, VITAS hashad received notification from our third party third-party intermediary that an additional $2.3$9.0 million iswas owed for Medicare cap in three programs arising duringfor the 2013 2014 and 2015through 2022 measurement periods. The amounts were automatically deducted from our semi-monthly PIP payments.  We dopayments and we did not believe that CMS is authorized under the sequestration authority or the statutory methodologyrecognize any revenue for establishing the Medicare cap to demand the $2.3 million under their “as if” methodology.  We have notthese disputed amounts, but recorded a receivable offset by a reserve as of September 30, 2017 for $480,000 ofequal amount. Due to recent court decisions, we are no longer appealing the potential exposure.  We have appealed CMS’s methodology change with the appropriate regulatory appeal board.

-6-

change. During the threeyear ended December 31, 2022, we reversed the related receivable and nine months ended September 30, 2016, respectively, $228,000 in Medicare cap was recorded for one program’s projected 2015 measurement period liability

reserve. There was no impact on the consolidated balance sheets or the consolidated statements of income as of and for the year ended December 31, 2022.

During the quarter ended March 31, 2023, we recorded $2.8 million in net Medicare cap revenue reduction related to three programs for the 2023 government fiscal year.

During the quarter ended March 31, 2022, we recorded $2.5 million in net Medicare cap revenue reduction related to two programs for the 2022 government fiscal year.

For VITAS’ patients in the nursing home setting in which Medicaid pays the nursing home room and board, VITAS serves as a pass-through between Medicaid and the nursing home. We are responsible for paying the nursing home for that patient’s room and board. Medicaid reimburses us for 95% of the amount we have paid. This results in a 5% net expense for VITAS related to nursing home room and board. This transaction creates a performance obligation in that VITAS is facilitating room and board being delivered to our patient. As a result, the 5% net expense is recognized as a contra-revenue account under ASC 606 in the accompanying financial statements.

The composition of patient care service revenue by payor and level of care for the quarter ended September 30, 2017.  During the nine months ended September 30, 2017, we recorded $247,000 for two programs cap liability for the 2013, 2014 and 2015 measurement periods of the amount recorded, $105,000 relates to the sequestration issue described above.


Shown below is the Medicare cap liability activity for the fiscal periods ended (in thousands):

  September 30, 
  2017  2016 
Beginning balance January 1, $235  $1,165 
Prior measurement periods  247   228 
Payments  (482)  (1,158)
Ending balance September 30, $-  $235 

Vitas provides charity care, in certain circumstances, to patients without charge when management of the hospice program determines, at the time services are performed, that the patient cannot afford payment.  There is no revenue or associated accounts receivable in the accompanying consolidated financial statements related to charity care.  The cost of charity care is calculated by taking the ratio of charity care days to total days of care and multiplying by total cost of care.  The cost of charity careMarch 31, 2023 is as follows (in thousands):

Medicare

Medicaid

Commercial

Total

Routine home care

$

250,916 

$

10,568 

$

5,566 

$

267,050 

Continuous care

18,508 

650 

783 

19,941 

Inpatient care

25,519 

2,432 

1,142 

29,093 

$

294,943 

$

13,650 

$

7,491 

$

316,084 

All other revenue - self-pay, respite care, etc.

3,021 

Subtotal

$

319,105 

Medicare cap adjustment

(2,750)

Implicit price concessions

(3,108)

Room and board, net

(2,769)

Net revenue

$

310,478 


-10-

Three months ended September 30,  Nine months ended September 30, 
2017  2016  2017  2016 
 $1,906   $1,711   $5,603   $5,231 



The composition of patient care service revenue by payor and level of care for the quarter ended March 31, 2022 is as follows (in thousands):

Medicare

Medicaid

Commercial

Total

Routine home care

$

241,337 

$

10,907 

$

5,392 

$

257,636 

Continuous care

17,977 

814 

787 

19,578 

Inpatient care

23,427 

1,963 

1,180 

26,570 

$

282,741 

$

13,684 

$

7,359 

$

303,784 

All other revenue - self-pay, respite care, etc.

3,007 

Subtotal

$

306,791 

Medicare cap adjustment

(2,500)

Implicit price concessions

(2,985)

Room and board, net

(2,117)

Net revenue

$

299,189 

Roto-Rooter

Roto-Rooter provides plumbing, drain cleaning, excavation, water restoration and other related services to both residential and commercial customers primarily in the United States. Services are provided through a network of company-owned branches, independent contractors and franchisees. Service revenue for Roto-Rooter is reported at the amount that reflects the ultimate consideration we expect to receive in exchange for providing services.

Roto-Rooter owns and operates branches focusing mainly on large population centers in the United States. Roto-Rooter’s primary lines of business in company-owned branches consist of plumbing, sewer and drain cleaning, excavation and water restoration. For purposes of ASC 606 analysis, plumbing, sewer and drain cleaning, and excavation have been combined into one portfolio and are referred to as “short-term core services”. Water restoration is analyzed as a separate portfolio. The following describes the key characteristics of these portfolios:

Short-term Core Services are plumbing, drain and sewer cleaning and excavation services. These services are provided to both commercial and residential customers. The duration of services provided in this category range from a few hours to a few days. There are no significant warranty costs or on-going obligations to the customer once a service has been completed. For residential customers, payment is received at the time of job completion before the Roto-Rooter technician leaves the residence. Commercial customers may be granted credit subject to internally designated authority limits and credit check guidelines. If credit is granted, payment terms are generally 30 days or less.

Each job in this category is a distinct service with a distinct performance obligation to the customer. Revenue is recognized at the completion of each job. Variable consideration consists of pre-invoice discounts and post-invoice discounts. Pre-invoice discounts are given in the form of coupons or price concessions. Post-invoice discounts consist of credit memos generally granted to resolve customer service issues. Variable consideration is estimated based on historical activity and recorded at the time service is completed.

Water Restoration Services involve the remediation of water and humidity after a flood. These services are provided to both commercial and residential customers. The duration of services provided in this category generally ranges from 3 to 5 days. There are no significant warranties or on-going obligations to the customer once service has been completed. The majority of these services are paid by the customer’s insurance company. Variable consideration relates primarily to allowances taken by insurance companies upon payment. Variable consideration is estimated based on historical activity and recorded at the time service is completed.

For both short-term core services and water restoration services, Roto-Rooter satisfies its performance obligation at a point in time. The services provided generally involve fixing plumbing, drainage or flood-related issues at the customer’s property. At the time service is complete, the customer acknowledges its obligation to pay for service and its satisfaction with the service performed. This provides evidence that the customer has accepted the service and Roto-Rooter is now entitled to payment. As such, Roto-Rooter recognizes revenue for these services upon completion of the job and receipt of customer acknowledgement. Roto-Rooter’s performance obligations for short-term core services and water restoration services relate to contracts with an expected duration of less than a year. Therefore, Roto-Rooter has elected to apply the optional exception provided in ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Roto-Rooter does not have significant unsatisfied or partially unsatisfied performance obligations at the time of initial revenue recognition for short-term core or water restoration services.

Roto-Rooter owns the rights to certain territories and contracts with independent third-parties to operate the territory under Roto-Rooter’s registered trademarks (“Independent Contractors”). Such contracts are for a specified term but cancellable by either party

-11-


without penalty with 90 days’ advance notice. Under the terms of these arrangements, Roto-Rooter provides certain back office support and advertising along with a limited license to use Roto-Rooter’s registered trademarks. The Independent Contractor is responsible for all day-to-day management of the business including staffing decisions and pricing of services provided. All performance obligations of Roto-Rooter cease at the termination of the arrangement.

Independent Contractors pay Roto-Rooter a standard fee calculated as a percentage of their cash collection from weekly sales. The primary value for the Independent Contractors under these arrangements is the right to use Roto-Rooter’s registered trademarks. Roto-Rooter recognizes revenue from Independent Contractors over-time (weekly) as the Independent Contractor’s labor sales are completed and payment from customers are received. Payment from Independent Contractors is also received on a weekly basis. The use of Roto-Rooter’s registered trademarks and advertising provides immediate value to the Independent Contractor as a result of Roto-Rooter’s nationally recognized brand. Therefore, over-time recognition provides the most faithful depiction of the transfer of services as the customer simultaneously receives and consumes the benefits provided. There is no significant variable consideration related to these arrangements.

Roto-Rooter has licensed the rights to operate under Roto-Rooter’s registered trademarks in other territories to franchisees. Each such contract is for a 10 year term but cancellable by Roto-Rooter for cause with 60 day advance notice without penalty. The franchisee may cancel the contract for any reason with 60 days advance notice without penalty. Under the terms of the contract, Roto-Rooter provides national advertising and consultation on various aspects of operating a Roto-Rooter business along with the right to use Roto-Rooter’s registered trademarks. The franchisee is responsible for all day- to-day management of the business including staffing decisions, pricing of services provided and local advertising spend and placement. All performance obligations of Roto-Rooter cease at the termination of the arrangement.

Franchisees pay Roto-Rooter a standard monthly fee based on the population within the franchise territory. The standard fee is revised on a yearly basis based on changes in the Consumer Price Index for All Urban Consumers. The primary value for the franchisees under this arrangement is the right to use Roto-Rooter’s registered trademarks. Roto-Rooter recognizes revenue from franchisees over-time (monthly). Payment from franchisees is also received on a monthly basis. The use of Roto-Rooter’s registered trademarks and advertising provides immediate value to the franchisees as a result of Roto-Rooter’s nationally recognized brand. Therefore, over-time recognition provides the most faithful depiction of the transfer of services as the customer simultaneously receives and consumes the benefits provided. There is no significant variable consideration related to these arrangements.

The composition of disaggregated revenue for the first quarter is as follows (in thousands):

March 31,

2023

2022

Drain cleaning

$

66,489 

$

66,687 

Plumbing

50,453 

47,672 

Excavation

59,576 

55,188 

Other

193 

165 

Subtotal - short term core

176,711 

169,712 

Water restoration

50,762 

40,360 

Independent contractors

23,300 

21,418 

Franchisee fees

1,351 

1,317 

Other

4,745 

4,191 

Gross revenue

256,869 

236,998 

Implicit price concessions and credit memos

(7,190)

(5,638)

Net revenue

$

249,679 

$

231,360 


-12-


3.    Segments


Service revenues and sales and after-tax earningsby business segment are shown in Note 2. After-tax income/(loss) by business segment are as follows (in thousands):

Three months ended March 31,

2023

2022

VITAS

$

24,764 

$

36,481 

Roto-Rooter

47,653 

43,937 

Total

72,417 

80,418 

Corporate

(18,296)

(16,249)

Net income

$

54,121 

$

64,169 


  Three months ended September 30,  Nine months ended September 30, 
  2017  2016  2017  2016 
Service Revenues and Sales
            
VITAS $288,951  $282,865  $855,977  $839,131 
Roto-Rooter  128,493   109,742   382,390   334,274 
Total $417,444  $392,607  $1,238,367  $1,173,405 
                 
After-tax Income/(Loss)
                
VITAS $26,454  $20,903  $14,797  $58,538 
Roto-Rooter  16,034   12,855   47,716   39,216 
Total  42,488   33,758   62,513   97,754 
Corporate  (7,051)  (6,929)  (18,888)  (21,200)
Net income $35,437  $26,829  $43,625  $76,554 

We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”.

-7-

4.    Earnings per Share


Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding. Earnings and diluted earnings per share are computed as follows (in thousands, except per share data):

Net Income

For the Three Months Ended March 31,

Income

Shares

Earnings per Share

2023

Earnings

$

54,121

14,966

$

3.62

Dilutive stock options

-

94

Nonvested stock awards

-

50

Diluted earnings

$

54,121

15,110

$

3.58

2022

Earnings

$

64,169

14,986

$

4.28

Dilutive stock options

-

165

Nonvested stock awards

-

41

Diluted earnings

$

64,169

15,192

$

4.22

  Net Income 
For the Three Months Ended September 30, Income  Shares  Earnings per Share 
2017         
Earnings $35,437   15,976  $2.22 
Dilutive stock options  -   616     
Nonvested stock awards  -   84     
Diluted earnings $35,437   16,676  $2.13 
             
2016            
Earnings $26,829   16,166  $1.66 
Dilutive stock options  -   294     
Nonvested stock awards  -   99     
Diluted earnings $26,829   16,559  $1.62 


  Net Income 
For the Nine Months Ended September 30, Income  Shares  Earnings per Share 
2017         
Earnings $43,625   16,068  $2.72 
Dilutive stock options  -   609     
Nonvested stock awards  -   86     
Diluted earnings $43,625   16,763  $2.60 
             
2016            
Earnings $76,554   16,443  $4.66 
Dilutive stock options  -   296     
Nonvested stock awards  -   112     
Diluted earnings $76,554   16,851  $4.54 

For the three months ended September 30, 2017, noMarch 31, 2023, there were 326,000 stock options and nonvested stock awards have been excluded infrom the calculationcomputation of dilutive earnings per share because they would have been anti-dilutive.


For the nine month periodthree months ended September 30, 2017,March 31, 2022, there were 7,304609,000 stock options excluded from the computation of diluteddilutive earnings per share because they would have been anti-dilutive.


 For the three and nine month periods ended September 30, 2016, 418,000 stock options were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.

5.    Long-Term Debt


and Lines of Credit

On June 30, 2014,28, 2022, we replaced our existing credit agreementfacility with the Third Amendeda fifth amended and Restatedrestated Credit Agreement (“20142022 Credit Agreement”Facilities”). Terms of the 20142022 Credit AgreementFacilities consist of a five-year $350 $450.0 million revolving credit facility andrevolver as well as a $100five-year $100.0 million term loan. Principal payments of $1.25 million on the term loan are due on the last day of each fiscal quarter, with a final payment due at the end of the agreement. The 20142022 Credit Agreement hasFacilities have a floating interest rate that is generally LIBORthe secured overnight financing rate (“SOFR”) plus aan additional tiered additional rate which varies based on our current leverage ratio. TheAs of March 31, 2023, the interest rate asis SOFR plus 100 basis points. The 2022 Credit Facilities include an expansion feature that provides the Company the opportunity to increase its revolver and or term loan by an additional $250.0. million.

We made prepayments totaling $75.0 million in the first quarter of September 30, 2017 is LIBOR plus 113 basis points.


2023, on the $100.0 million term loan. We plan to pay the remaining balance of $21.3 million on April 28, 2023. There are no prepayment penalties associated with this repayment. There are no significant deferred debt issuance costs capitalized related to the term loan. This will reduce the borrowing capacity of the 2022 Credit Facilities from $550.0 million to $450.0 million.


-8-

-13-



The debt outstanding as of September 30, 2017March 31, 2023 consists of the following:

Revolver

$

-

Term loan

21,250 

Total

21,250 

Current portion of long-term debt

(5,000)

Long-term debt

$

16,250 


Revolver $5,000 
Term loan  77,500 
Total  82,500 
Current portion of long-term debt  (10,000)
Long-term debt $72,500 

Debt issuance costs associated with the prior credit agreement were not written off as the lenders did not change and their relative percentage participation in the facility was substantially the same. Deferred financing cost of $1.5 million for the 2022 Credit Facilities were capitalized during the quarter ended June 30, 2022.

Scheduled principal payments of the term loan2022 Credit Facilities are as follows:

2023

$

3,750 

2024

5,000 

2025

5,000 

2026

5,000 

2027

2,500 

$

21,250 

2017 $2,500 
2018  10,000 
2019  65,000 
  $77,500 

The 20142022 Credit Agreement containsFacilities contain the following quarterly financial covenants:

covenants effective as of March 31, 2023:


Description

Requirement

Description

Requirement

Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA)

< 3.50 to 1.00

Fixed Charge

Interest Coverage Ratio (Consolidated Free Cash Flow/Adj. EBITDA/Consolidated Fixed Charges)Interest Expense)

> 1.503.00 to 1.00

Annual Operating Lease Commitment< $50.0 million


We are in compliance with all debt covenants as of September 30, 2017.March 31, 2023. We have issued $35.6$45.3 million in standby letters of credit as of September 30, 2017March 31, 2023, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 20142022 Credit Agreement.Facilities. As of September 30, 2017,March 31, 2023, we have approximately $309.4$404.7 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility.


6.    Other Operating Income/(Expenses)

  Three months ended September 30,  Nine months ended September 30, 
  2017  2016  2017  2016 
             
Potential litigation settlement $-  $-  $90,000  $- 
Program closure (income)/expenses  (371)  -   1,138   - 
Retirement expenses  -   -   -   4,491 
Total other operating (income)/expenses $(371) $-  $91,138  $4,491 

During the three and nine months ended September 30, 2017, the Company recorded a credit for recovery of previously expensed costs of $371,000 and a netExpense – Net

Other expense of $1.1 million, respectively, related to the closure of three Alabama programs at VITAS.


During the nine months ended September 30, 2017, the Company recorded $90 million for a potential litigation settlement.  See footnote 11 for further discussion.

During the nine months ended September 30, 2016, the Company recorded early retirement related costs and accelerated stock-based compensation expense of approximately $4.5 million pretax and $2.8 million after-tax, related to the early retirement of VITAS’ former Chief Executive Officer.
-9-

7.   Other Income Net

Other income -- net comprises the following (in thousands):

Three months ended March 31,

2023

2022

Market value adjustment on assets held in

deferred compensation trust

$

(321)

$

(3,934)

Interest income

150 

73 

Other-net

68 

(1)

Total other (expense)/income - net

$

(103)

$

(3,862)

7.    Leases

Chemed and each of its operating subsidiaries are service companies. As such, real estate leases comprise the largest lease obligation (and conversely, right of use asset) in our lease portfolio. VITAS has leased office space, as well as space for inpatient units (“IPUs”) and/or contract beds within hospitals. Roto-Rooter mainly has leased office space. Our leases have remaining terms of under 1 year to 10 years, some of which include options to extend the lease for up to 5 years, and some of which include options to terminate the lease within 1 year.

-14-

  Three months ended September 30,  Nine months ended September 30, 
  2017  2016  2017  2016 
Market value adjustment on assets held in            
deferred compensation trust $1,417  1,656  5,619  1,857 
Loss on disposal of property and equipment  (146)  (134)  (481)  (224)
Interest income  51   119   297   301 
Other - net  1   (1)  4   (1)
Total other income - net 1,323  1,640  5,439  1,933 



Roto-Rooter purchases equipment and leases it to certain of its Independent Contractors. We analyzed these leases in accordance with ASC 842 and determined they are operating leases. As a result, Roto-Rooter will continue to capitalize the equipment underlying these leases, depreciate the equipment and recognize rental income.

We do not currently have any finance leases, therefore all lease information disclosed is related to operating leases.

The components of balance sheet information related to leases were as follows:

March 31,


December 31,

2023

2022

Assets

Operating lease assets

$

131,219 

$

135,662 

Liabilities

Current operating leases

38,291 

38,996 

Noncurrent operating leases

106,212 

110,513 

Total operating lease liabilities

$

144,503 

$

149,509 

The components of lease expense for the first quarter are as follows (in thousands):

Three months ended March 31,

2023

2022

Lease Expense (a)

Operating lease expense

$

14,906 

$

14,903 

Sublease income

(23)

(45)

Net lease expense

$

14,883 

$

14,858 

(a)Includes short-term leases and variable lease costs, which are immaterial. Included in both cost of services provided and goods sold and selling, general and administrative expenses.

The components of cash flow information related to leases were as follows:

Three months ended March 31,

2023

2022

Cash paid for amounts included in the measurement of lease liabilities

Operating cash flows from leases

$

12,668 

$

12,489 

Leased assets obtained in exchange for new operating lease liabilities

$

6,845 

$

20,453 

Weighted Average Remaining Lease Term at March 31, 2023

Operating leases

4.58

years

Weighted Average Discount Rate at March 31, 2023

Operating leases

2.64

%


-15-


Maturity of Operating Lease Liabilities (in thousands)

2023

$

34,439 

2024

37,667 

2025

30,078 

2026

23,143 

2027

12,607 

Thereafter

16,065 

Total lease payments

$

153,999 

Less: interest

(9,496)

Total liability recognized on the balance sheet

$

144,503 

For leases commencing prior to April 2019, minimum rental payments exclude payments to landlords for real estate taxes and common area maintenance. Operating lease payments include $2.7 million related to extended lease terms that are reasonably certain of being exercised and exclude $144,000 of lease payments for leases signed but not yet commenced.

8.    Stock-Based Compensation Plans


On February 17, 2017,2023, the Compensation/Incentive Committee of the Board of Directors (“CIC”) granted 7,3046,078 Performance Stock Units (“PSUs”) that vest contingent upon the achievement of certain total shareholdersshareholder return (“TSR”) targets as compared to the TSR of a group of peer companies for the three-year period ending December 31, 2019,2025, the date at which such awards vest. The cumulative compensation cost of the TSR-based PSU award to be recorded over the three yearthree-year service period is $1.7$5.1 million.


On February 17, 2017,2023, the CIC also granted 7,3046,078 PSUs that vest contingent upon the achievement of certain earnings per share (“EPS”) targets for the three-year period ending December 31, 2019.2025. At the end of each reporting period, the Company estimates the number of shares that it believes will ultimately be earned and records thatthe corresponding expense over the service period of the award. We currently estimate the cumulative compensation cost of the EPS-based PSUs to be recorded over the three yearthree-year service period is $1.3$4.2 million.


9.   Independent Contractor Operations


The Roto-Rooter segment sublicenses with 69 independent contractors to operate certain plumbing repair, excavation, water restoration and drain cleaning businesses in lesser-populated areas of the United States and Canada.  We had notes receivable from our independent contractors as of September 30, 2017 totaling $1.5 million (December 31, 2016 - $1.7 million).  In most cases these loans are fully or partially secured by equipment owned by the contractor.  The interest rates on the loans range from 0% to 7% per annum and the remaining terms of the loans range from less than 3 months to approximately 5 years at September 30, 2017.  We recorded the following from our independent contractors (in thousands):
  Three months ended September 30,  Nine months ended September 30, 
  2017  2016  2017  2016 
Revenues 10,455  9,823  32,632  29,451 
Pretax income  6,311   5,835   19,742   18,015 


10.    Retirement Plans

All of the Company’s plans that provide retirement and similar benefits are defined contribution plans. These expenses include the impact of market gains and losses on assets held in deferred compensation plans and are recorded in selling, general and administrative expenses. ExpensesNet gains for the Company’s retirement and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands):

Three months ended March 31,

2023

2022

$

5,873

$

2,917


Three months ended September 30,  Nine months ended Nine 30, 
2017  2016  2017  2016 
 $4,427   $4,423   $15,136   $10,809 
-10-

11.

10.    Legal and Regulatory Matters


The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, which can result in penalties including repayment obligations, funding withholding, or debarment, as well as to lawsuits, including qui tam actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. Other than as described below, with respect to U.S. v. Vitas, it is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or reasonably estimable.


Regulatory Matters and Litigation


On May 2, 2013,October 30, 2017, the government filedCompany entered into a settlement agreement to resolve civil litigation under the False Claims Act complaint againstbrought by the CompanyUnited States Department of Justice (“DOJ”) on behalf of the OIG and certain of its hospice-related subsidiariesvarious relators concerning VITAS, filed in the U.S. District Court forof the Western District of Missouri, United States v.Missouri. The Company denied any violation of law and agreed to settlement without admission of wrongdoing.

In connection with the settlement, VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”and certain of its subsidiaries entered into a corporate integrity agreement (“CIA”).  Prior on October 30, 2017. The CIA formalizes various aspects of VITAS’ already existing Compliance Program and contains requirements

-16-


designed to that date,document compliance with federal healthcare program requirements. It has a term of five years during which it imposes monitoring, reporting, certification, oversight, screening and training obligations, certain of which had previously been implemented by VITAS. Although the Companyfive-year term has lapsed, VITAS still has certain obligations under the agreement including having an Independent Review Organization perform audit and review functions and to prepare reports regarding compliance with federal healthcare programs for the fifth year of the agreement. In the event of breach of the CIA, VITAS could become liable for payment of stipulated penalties or could be excluded from participation in federal healthcare programs.

On October 16, 2020, VITAS received various qui tam lawsuits and subpoenas froma Civil Investigative Demand (“CID”) issued by the U.S. Department of Justice and OIG that have been previously disclosed.  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004,(“DOJ”) pursuant to the Company, submitted or causedFalse Claims Act concerning allegations of the submission of false claims for hospice services for which reimbursement was sought from federal healthcare programs, including Medicare. The CID requested information regarding 32 patients from our Florida operations. On November 30, 2022, VITAS received a Letter of Declination from the DOJ, informing VITAS that the United States was declining to intervene in this case giving rise to the CID, United States Ex. Rel. O’Keefe v VITAS Healthcare Corporation, et al. that was unsealed on November 15, 2022. On April 6, 2023, the relator dismissed the case, without prejudice, with the consent of the United States.

VITAS is one of a group of hospice providers selected by the OIG’s Office of Audit Services (“OAS”) for inclusion in an audit of the provision of elevated level-of-care hospice services. On July 14, 2022, VITAS received the final audit report from OAS. Per this report, the OAS audit examined VITAS inpatient and continuous care claims for the period April 2017 to March 2019. The audit covered a total population of 50,850 claims representing total Medicare program by (a) billingreimbursement of $210.0 million during this two-year time period. From this population, OAS selected 100 claims, representing $688,000 of reimbursement, for detailed review. The final OAS audit report includes a series of recommendations, including that VITAS repay approximately $140.0 million of the $210.0 million VITAS received from Medicare for continuous home carehospice services whenduring this two-year period, despite the patients were not eligible,fact that at the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the coststime of the action, plus interest.  The defendants filed a motion to dismiss on September 24, 2013.  release of the results of the audit, many of the disputed claims were time-barred from being challenged. VITAS believes that the OAS audit process and related final report contains significant flaws including its methodology, medical reviews, technical reviews, proposed extrapolation methodology, and contravenes the “reasonable physician standard” set forth in the appliable Aseracare precedent.

On September 30, 2014, the Court denied the motion, exceptAugust 29, 2022, six weeks subsequent to the extent that claims were filed before July 24, 2002. On November 13, 2014,OAS finalizing its audit, VITAS received a demand letter from its Medicare Administrative Contractor (“MAC”) seeking repayment of $50.3 million. This demand letter is $90.0 million lower than the government filedfinal OAS audit recommendation, as a Second Amended Complaint.  The Second Amended Complaint changed and supplemented somesignificant portion of the allegations, but did not otherwise expand the causes of action or the nature100 claims reviewed are closed pursuant to applicable law and ineligible to be reopened. VITAS timely filed its initial appeal of the relief sought against VITAS.overpayment decision and deposited $50.3 million under the “Immediate Recoupment” process to preserve its appeal rights. After the initial redetermination process, VITAS filed its Answer to the Second Amended Complaint on August 11, 2015.  Based on recent case developments, including recent mediation discussions with the U.S. Department of Justice, we believe it probable that this matter will be settled, to include payments of $55.8 million after-tax ($90.0 million pretax) including attorneys’ fees.  A final settlement will require the parties to resolve several outstanding issues, and to draft and negotiate definitive documentation.  There can be no assurance that such a final definitive settlement will be reached on these, or other, terms.  For additional procedural history of this litigation, please refer to our prior quarterly and annual filings.  The costs incurred related to U.S. v. Vitas and related regulatory matters were $935,000 and $599,000 for the quarters ended September 30, 2017 and 2016, respectively.  For the nine months ended September 30, 2017 and 2016, the net costs were $5.2 million and $4.1 million respectively.


Net income for the nine months ended September 30, 2017 includes the $55.8was refunded $2.5 million of after-tax expense ($90 million pre-tax) for the accrual of such potential litigation settlement.  As required by GAAP,amount deposited and continues to appeal the Company accrues for contingent loss claims in its financial statements when it is probable that a liabilityremaining claims. The amount deposited has been incurred and the amount can be reasonably estimated.

 The Company and certain current and former directors and officers are defendants in a case captioned In re Chemed Corp. Shareholder Derivative Litigation, No. 13 Civ. 1854 (LPS) (CJB) (D. Del.), which was consolidated on February 2, 2015.

On February 2, 2015, the Court appointed KBC Asset Management NV the sole lead plaintiff and its counsel, the sole lead and liaison counsel. On March 3, 2015, Lead Plaintiff KBC designated its Complaintrecorded as the operative complaintan “other long-term asset” in the consolidated proceedings and defendants renewed a previously filed motionbalance sheets, as detailed in Note 13. VITAS intends to dismiss thosecontinue vigorously defending the claims and allegations.  The consolidated Complaint named fourteen individual defendants, together withbrought; however, the Company as nominal defendant.  The Complaint alleges a claim for breach of fiduciary duty againstcannot predict the individual defendants for allegedly permitting the Company to submit false claims to the U.S. government.  The Complaint seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.  On May 12, 2016, the Court issued a Memorandum Order granting Chemed’s motion to dismiss, and  dismissing Lead Plaintiff KBC’s Complaint without prejudice to KBC’s opportunity to file within 30 days of the date of the Court’s Order (i.e., by June 13, 2016) an amended Complaint addressing the deficiencies in its duty of loyalty claim.  Lead Plaintiff KBC did not file an amended Complaint within the time specified by the Court.
-11-

However, on June 13, 2016, counsel for Chemed shareholder Michael Kvint filed a letter with the Court requesting a two-week extension to file a motion to substitute Mr. Kvint as lead plaintiff, in place of Lead Plaintiff KBC and to file an amended Complaint.  Alternatively, counsel for Mr. Kvint requested that any dismissal of the action be with prejudice to KBC only.  On June 14, 2016, Chemed filed a reply letter with the Court, reserving its rights to oppose any motion filed by Mr. Kvint and, if warranted, to oppose any other actions taken by Mr. Kvint to proceed with the action (including by filing an untimely amended Complaint).  On June 21, 2016, the Court entered an Oral Order providing Mr. Kvint until June 30, 2016 to file a Motion to Substitute and Motion for Leave to File an Amended Complaint.  On that date, Mr. Kvint filed, under seal, a Motion to Substitute Plaintiff and File Amended Complaint, and attached a Proposed Amended Complaint.    Mr. Kvint’s motion was fully briefed by the parties.  On April 25, 2017, Magistrate Judge Burke issued a Report and Recommendation recommending that the Court permit Mr. Kvint to intervene as Lead Plaintiff and grant leave to amend the complaint to replead the duty of loyalty claim only.  On May 16, 2017, Chief Judge Stark signed an Order adopting that Report and Recommendation.  Plaintiff Kvint filed a Corrected Amended Complaint on May 30, 2017.  On September 13, 2017, the Court entered an order dismissing with prejudice the claims against defendants Timothy S. O’Toole and Joel F. Gemunder and permitting Defendants to file a Motion to Dismiss the Corrected Amended Complaint oneventual outcome, or before September 29, 2017, with Plaintiff’s Answering Brief to be filed on or before December 1, 2017, and Defendants’ Reply Brief to be filed on or before December 29, 2017.  Defendants filed their Motion to Dismiss timely.  As the Company has previously disclosed, the legal fees and costs associated with defending against this lawsuit are presently being paid by insurance. For additional procedural history of this litigation, please refer to our prior quarterly and annual filings.

Jordan Seper, (“Seper”) a Registered Nurse at VITAS' Inland Empire program from May 12, 2014 to March 21, 2015, filed a lawsuit in San Francisco Superior Court on September 26, 2016.  She alleged VITAS Healthcare Corp of CA (“VITAS CA”) (1) failed to provide minimum wage for all hours worked; (2) failed to provide overtime for all hours worked; (3) failed to provide a second meal period; (4) failed to provide rest breaks; (5) failed to indemnify for necessary expenditures; (6) failed to timely pay wages due at time of separation; and (7) engaged in unfair business practices.  Seper seeks a state-wide class action of current and former non-exempt employees employed with VITAS in California within the four years preceding the filing of the lawsuit.  She seeks court determination that this action may be maintained as a class action for the entire California class and subclasses, designation as class representative, declaratory relief, injunctive relief, damages (including wages for regular or overtime hours allegedly worked but not paid, premium payments for missed meal or rest periods, and unreimbursed expenses), all applicable penalties associated with each claim, pre and post-judgment interest, and attorneys' fees and costs.  Seper served VITAS CA with the lawsuit,  Jordan A. Seper on behalf of herself and others similarly situated v. VITAS Healthcare Corporation of California, a Delaware corporation; VITAS Healthcare Corp of CA, a business entity unknown; and DOES 1 to 100, inclusive; Los Angeles Superior Court Case Number BC 642857 on October 13, 2016.

On November 14, 2016, the Parties filed a Stipulation to transfer the venue of the lawsuit from San Francisco to Los Angeles.  The Los Angeles Superior Court Complex Division accepted transfer of the case on December 6, 2016 and stayed the case.  On December 16, 2016, VITAS CA filed its Answer and served written discovery on Seper.

 Jiwan Chhina ("Chhina"), hired by VITAS as a Home Health Aide on February 5, 2002, is currently a Licensed Vocational Nurse for VITAS' San Diego program.  On September 27, 2016, Chhina filed a lawsuit in San Diego Superior Court, alleging (1) failure to pay minimum wage for all hours worked; (2) failure to provide overtime for all hours worked; (3) failure to pay wages for all hours at the regular rate; (4) failure to provide meal periods; (5) failure to provide rest breaks; (6) failure to provide complete and accurate wage statements; (7) failure to pay for all reimbursement expenses; (8) unfair business practices; and (9) violation of the California Private Attorneys General Act.  Chhina seeks to pursue these claims in the form of a state-wide class action of current and former non-exempt employees employed with VITAS in California within the four years preceding the filing of the lawsuit.  He seeks court determination that this action may be maintained as a class action for the entire California class and subclasses, designation as class representative, declaratory relief, injunctive relief, damages (including wages for regular or overtime hours allegedly worked but not paid, premium payments for missed meal or rest periods, and unreimbursed expenses), all applicable penalties associated with each claim, pre-judgment interest, and attorneys' fees and costs.  Chhina served VITAS CA with the lawsuit, Jiwann Chhina v. VITAS Health Services of California, Inc., a California corporation; VITAS Healthcare Corporation of California, a Delaware corporation; VITAS Healthcare Corporation of California, a Delaware corporation dba VITAS Healthcare, Inc.; and DOES 1 to 100, inclusive; San Diego Superior Court Case Number 37-2015-00033978-CU-OE-CTL on November 3, 2016.  On December 1, 2016, VITAS CA filed its Answer and served written discovery on Chhina.

On May 19, 2017, Chere Phillips (a Home Health Aide in Sacramento) and Lady Moore (a former Social Worker in Sacramento) filed a lawsuit against VITAS Healthcare Corporation of California in Sacramento County Superior Court, alleging claims for (1) failure to pay all wages due; (2) failure to authorize and permit rest periods; (3) failure to provide off-duty meal periods; (4) failure to furnish accurate wage statements; (5) unreimbursed business expenses; (6) waiting time penalties; (7) violations of unfair competition law; and (8) violation of the Private Attorney General Act.  The case is captioned: Chere Phillips and Lady Moore v. VITAS Healthcare Corporation of California, Sacramento County Superior Court, Case No. 34-2017-0021-2755.  Plaintiffs sought to pursue these claims in the form of a state-wide class action of current and former non-exempt employees employed with VITAS CA in California within the four years preceding the filing of the lawsuit.  Plaintiffs served VITAS with the lawsuit on June 5, 2017. VITAS CA timely answered the Complaint generally denying the Plaintiffs’ allegations.  The Court has stayed all class discovery in this case pending resolution of the November 10, 2017 mediation in the Seper and Chhina cases.
-12-

There are currently three other lawsuits against VITAS pending in the superior courts of other California counties that contain claims and class periods that substantially overlap with Phillips’ and Moore’s claims.  These are Seper, v. VITAS Healthcare Corp of California et al., filed on September 26, 2016 in Los Angeles County Superior Court BC 642857; Chhina v. VITAS Health Service, Inc. et al., filed on September 27, 2016 in San Diego County Superior Court, 34-2015-00033998 CU_OE_CTL; both described above and Williams v. VITAS Healthcare Corporation of California, filed on May 22, 2017 in Alameda County Superior Court, RG 17853886.

Jazzina Williams’ (a Home Health Aide in Sacramento) lawsuit alleges claims for (1) failure to pay all wages due; (2) failure to authorize and permit rest periods; (3) failure to provide off-duty meal periods; (4) failure to furnish accurate wage statements; (5) unreimbursed business expenses; (6) waiting time penalties; and (7) violations of the Private Attorney General Act.  Williams seeks to pursue these claims in the form of a state-wide class action of current and former non-exempt employees.  Plaintiff served VITAS with the lawsuit on May 31, 2017.  VITAS timely answered the Complaint generally denying Plaintiff’s allegations.  Williams is pursuing discovery of her individual claims and has agreed to a stay of class discovery pending outcome of a November 10, 2017 mediation of the Seper and Chhina cases.  Defendant filed and served each of Plaintiffs Williams, Phillips, and Moore with a Notice of Related Cases on July 19, 2017.

Defendant understands that the Seper and Chhina cases will be effectively consolidated in Los Angeles County Superior court: Chhina will be dismissed as a separate action and joined with Seper through the filing of an amended complaint in Seper in which Chhina is also identified as a named plaintiff.

The Company is not able to reasonably estimate the probability ofany potential loss, or range of loss forfrom any of these lawsuitssuch claims at this time.

The Company intends to defend vigorously against the allegations in each of the above lawsuits. 

Regardless of the outcome of any of the preceding matters, dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, withholding of governmental funding, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.


12.

11.    Concentration of Risk


During

As of March 31, 2023, and December 31, 2022, approximately 70% and 64%, respectively, of VITAS’ total accounts receivable balance were from Medicare and 24% and 29%, respectively, of VITAS’ total accounts receivable balance were due from various state Medicaid or managed Medicaid programs. Combined accounts receivable from Medicare, Medicaid, and managed Medicaid represent approximately 73% of the quarter consolidated net accounts receivable in the accompanying consolidated balance sheets as of March 31, 2023.

VITAS hadhas a pharmacy services agreementscontract with one service provider to providefor specified pharmacy services for VITAS andrelated to its hospice patients.operations. Similarly, effective January 1, 2022, VITAS madeobtains the majority of its medical supplies from a single vendor. A large majority of VITAS’ pharmaceutical and medical supplies purchases from this provider of $7.7 and $24.8 million for the three and nine months ended September 30, 2017, respectively. Vitas made purchases from two providers of $9.5 and $26.9 million for the three and nine months ended September 30, 2016, respectively.  Purchasesare from these providers were more than 90% of all pharmacy services usedvendors. The pharmaceutical and medical supplies purchased by VITAS during each period presented.


13.are available through many providers in the United States. However, a disruption from VITAS’ main service providers could adversely impact VITAS’ operations, including temporary logistical challenges and increased cost associated with getting medication and medical supplies to our patients.

12.    Cash Overdrafts and Cash Equivalents


There are $468,000 inwere no cash overdrafts payable included in accounts payable at September 30, 2017 (DecemberMarch 31, 2016 - $8.6 million).


2023 and December 31, 2022.

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. The amount invested was less than $100,000not material for each balance sheet date presented.


-17-


14.

13.     OtherAssets

Other assets comprise the following (in thousands):

March 31,

December 31,

2023

2022

Deposit with OAS

$

48,422 

$

50,274 

Cash surrender value life insurance

3,640 

3,636 

Noncurrent advances and deposits

2,196 

2,368 

Deferred debt costs

1,646 

1,703 

Other long-term receivable

1,607 

1,826 

$

57,511 

$

59,807 

14.     Other Current Liabilities

March 31,

December 31,

2023

2022

Healthcare worker retention bonus

$

30,551 

$

19,634 

Medicare Cap

10,365 

14,380 

All other

28,388 

26,990 

$

69,304 

$

61,004 

There are no individual amounts exceeding 5% of the total current liabilities in the “all other” line item for either period presented.

15.    Financial Instruments


FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements. Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities. Level 2 measurements use significant other observable inputs. Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions. In recording the fair value of assets and liabilities, companies must use the most reliable measurement available.

-13-

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of September 30, 2017March 31, 2023 (in thousands):

Fair Value Measure

Carrying Value

Quoted Prices in Active Markets for Identical Assets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Investments of deferred compensation plans held in trust

$

97,436 

$

97,436 

$

-

$

-

Long-term debt and current portion of long-term debt

21,250 

-

21,250 

-


-18-

     Fair Value Measure 
  Carrying Value  
Quoted Prices in
Active Markets for
Identical Assets
 (Level 1)
  
Significant Other Observable Inputs
(Level 2)
  
Significant
Unobservable
Inputs (Level 3)
 
Mutual fund investments of deferred            
compensation plans held in trust $60,445  $60,445  $-  $- 
Total debt  82,500   -   82,500   - 


The following shows the carrying value, fair value and the hierarchy for our financial instruments as of December 31, 20162022 (in thousands):

Fair Value Measure

Carrying Value

Quoted Prices in Active Markets for Identical Assets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Investments of deferred compensation plans held in trust

$

93,196 

$

93,196 

$

-

$

-

Long-term debt and current portion of long-term debt

97,500 

-

97,500 

-


     Fair Value Measure 
  Carrying Value  
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
  
Significant Other Observable Inputs
(Level 2)
  
Significant
Unobservable
Inputs (Level 3)
 
Mutual fund investments of deferred            
compensation plans held in trust $54,389  $54,389  $-  $- 
Total debt  108,750   -   108,750   - 

For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments. As further described in FootnoteNote 5, our outstanding long-term debt and current portion of long-term debt havehas a floating interest ratesrate that areis reset at short-term intervals, generally 30 or 60 days. The interest rate we pay also includes an additional amount based on our current leverage ratio. As such, we believe our borrowings reflect significant nonperformance risks, mainly credit risk. Based on these factors, we believe the fair value of our long-term debt and current portion of long-term debt approximate theapproximates its carrying value.


15.

16.    Capital Stock Repurchase Plan Transactions


We repurchased the following capital stock for the threestock:

Three months ended March 31,

2023

2022

Total cost of repurchased shares (in thousands)

$

-

$

27,353 

Shares repurchased

-

57,500 

Weighted average price per share

$

-

$

475.71 

In May and nine months ended September 30, 2017 and 2016:

  Three months ended September 30,  Nine months ended September 30, 
  2017  2016  2017  2016 
             
Total cost of repurchased shares (in thousands) $9,576  $-  $94,640  $102,313 
Shares repurchased  50,000  -   500,000   780,134 
Weighted average price per share $191.52  $-  $189.28  $131.15 

In March 2017,November 2021, the Board of Directors authorized an additional $100.0a total of $600.0 million for additional stock repurchase under Chemed’s existing share repurchase program. We currently have $55.5 million$87.9 million of authorizationauthorization remaining under this share repurchase plan.

-14-

16.   Recent Accounting Standards

17.    Acquisitions

In May 2014,2022, VITAS purchased the FASB issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers” which provides additional guidance to clarifyhospice assets of one Florida provider for $1.24 million in cash. Roto-Rooter completed the principles for recognizing revenue.  The standard and subsequent amendments are intended to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide more useful information to users through improved disclosure requirements, and simplify the preparationacquisition of financial statements. This guidance and subsequent amendments are effective for fiscal years beginning after December 15, 2017.    At both VITAS and Roto-Rooter, we have performed an initial analysis to determine the appropriate aggregation of customers into portfolios with similar collection and service requirement characteristics.  This analysis is currently being refined to ensure the portfolios identified will result in a materially consistent revenue recognition pattern that would result as if each customer were evaluated separately.  Additionally, based on our initial evaluation, we believe the majority of our provision for bad debts, currently classified in selling, general and administrative expense in our Statements of Income, will be reclassified as a contra-revenue as it will be considered an implicit price concession at the time service is performed.  For the nine month period ended September 30, 2017, our total provision for bad debt is $13.0 million.  We anticipate a modified retrospective adoption of the ASU.


In February 2016, the FASB issued Accounting Standards Update “ASU No. 2016-02 – Leases” which introduces a lessee model that brings most leases on to the balance sheets and updates lessor accounting  to align with changes in the lessee modelthree franchises and the revenue recognition standard.   The guidancerelated assets in New Jersey for a total of $2.29 million in cash.

Goodwill is effectiveassessed for fiscal years beginning after December 15, 2018.  Basedimpairment on the provisionsa yearly basis as of the ASU, we anticipate a material increase in both assets and liabilities when our current operating lease contracts are recorded on the balance sheet.  We do not currently have a specific estimate of the impact.


In August 2016, the FASB issued Accounting Standards Update “ASU No. 2016-15 – Cash Flow Classification” which amends guidance on the classification of certain cash receipts and payments in the statement of cash flows.  The primary purpose of ASU 2016-15October 1. All goodwill recognized is to reduce diversity in practice related to eight specific cash flow issues.  The guidance in this ASU is effectivedeductible for fiscal years beginning after December 15, 2017.    We have analyzed the impact of ASU 2016-15 on our statement of cash flows and do not expect it to have a material effect.

In January 2017, the FASB issued Accounting Standards Update “ASU No. 2017-4 – Intangibles – Goodwill and Other”.  To simplify the subsequent measurement of goodwill, the FASB eliminated Step 2 from the goodwill impairment test.  The guidance in the ASU is effective for the Company in fiscal years beginning after December 15, 2019.  Early adoption is permitted.  We anticipate adoption of this standard will have no impact on our consolidated financial statements.
17.   Goodwill

tax purposes.

Shown below is movement in Goodwill (in thousands):

VITAS

Roto-Rooter

Total

Balance at December 31, 2022

$

334,063 

$

247,232 

$

581,295 

Foreign currency adjustments

-

(9)

(9)

Balance at March 31, 2023

$

334,063 

$

247,223 

$

581,286 

  Vitas  Roto-Rooter  Total 
Balance at December 31, 2016 $328,301  $144,065  $472,366 
Business combinations  -   481   481 
Foreign currency adjustments  -   177   177 
Balance at September 30, 2017 $328,301  $144,723  $473,024 

During 2017, we completed one business combination within the Roto-Rooter segment for $525,000 in cash to increase our market penetration.


-15-

-19-



Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations


Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractorsIndependent Contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.


The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little or no exposure related to customers, vendors, or employees in other regions of the world.

The following is a summary of the key operating results (in thousands except per share amounts):

Three months ended March 31,

2023

2022

Service revenues and sales

$

560,157 

$

530,549 

Net income

$

54,121 

$

64,169 

Diluted EPS

$

3.58 

$

4.22 

Adjusted net income

$

72,867 

$

72,780 

Adjusted diluted EPS

$

4.82 

$

4.79 

Adjusted EBITDA

$

111,033 

$

110,208 

Adjusted EBITDA as a % of revenue

19.8 

%

20.8 

%

  Three months ended September 30,  Nine months ended September 30, 
  2017  2016  2017  2016 
Service revenues and sales $417,444  $392,607  $1,238,367  $1,173,405 
Net income $35,437  $26,829  $43,625  $76,554 
Diluted EPS $2.13  $1.62  $2.60  $4.54 
Adjusted net income $35,772  $28,643  $102,174  $86,625 
Adjusted diluted EPS $2.15  $1.73  $6.10  $5.14 
Adjusted EBITDA $67,604  $57,387  $195,921  $170,391 
Adjusted EBITDA as a % of revenue  16.2%  14.6%  15.8%  14.5%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 30-32.


Both VITAS and Roto-Rooter have significant operations in Houston and south Florida.  For the three and nine months ended September 30, 2017 we did not experience any material business interruptions or loss of assets related to the hurricanes in Houston or Florida.

Net income for the nine months ended September 30, 2017 includes $55.8 million ($3.33 per share) of after-tax expense ($90 million pre-tax) for the accrual of a potential litigation settlement related to the May 2, 2013 complaint filed against the Company by the U.S. Department of Justice.  As required by U.S. Generally Accepted Accounting Principles, the Company accrues for contingent loss claims in its financial statements when it is probable that a liability has been incurred and the amount can be reasonably estimated.  Based on recent case developments, including recent mediation discussions with the U.S. Department of Justice, the Company believes that it is probable that this matter will be settled, and that such settlement will include settlement payments and relator attorney fees, by the Company of approximately the accrued amount.  However, the achievement of a final, definitive settlement will require the parties to resolve several outstanding issues (and draft and negotiate related definitive documentation), and there can be no assurance that such a final, definitive settlement will be reached and agreed on these or other terms.

27-28.

For the three months ended September 30, 2017,March 31, 2023, the increase in consolidated service revenues and sales was driven by a 17.1%7.9% increase at Roto-Rooter and a 2.2%3.8% increase at VITAS. The increase in service revenues at Roto-Rooter was driven mainly by an increase in all major service lines. Of Roto-Rooter’s total revenue increase, 49.1% is related toplumbing, excavation, and water restoration. The increase in service revenues at VITAS wasis comprised primarily of a 3.0% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.9%, partially offset by 200-basis points as a result of Medicare reimbursement rates increasing 1.3%, a 2.8% increaseCMS reimplementing the 2.0% sequestration cut that was suspended at the start of the pandemic in days of care, offset by acuity2020. Acuity mix shift which negatively impacted revenue 2.2%had minimal impact in the quarter when compared to the prior year period.  Adjusted EBITDA asrevenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes negatively impacted revenue growth by 10-basis points.

The pandemic has resulted in a percentsignificant shortage of revenue increased 160 basis points when comparedlicensed healthcare workers industry wide. VITAS has not been immune to the prior year quarter mainly asthis shortage. As a result, on July 1, 2022, VITAS implemented a hiring and retention bonus program for its licensed healthcare workers. It is a temporary program intended to help VITAS attract and retain licensed healthcare workers in light of mix shiftthe pandemic induced healthcare worker shortage. An eligible employee must continue in levelsemployment for a period of careone-year from July 1st to receive a bonus. Additionally, employees hired between July 1, 2022 and improved cost managementJune 30, 2023 are eligible if they continue employment for high acuity care.a one-year period from their hire date. The Company accrued $10.9 million in the first quarter of 2023 related to this retention bonus program. See page 3329 for additional VITAS operating metrics.

While significant continuing issues related to the COVID-19 pandemic appear to be over or materially mitigated, we will continue to monitor any impact on our business including employees, customers, patients, and supply vendors.

While many companies have been adversely impacted by the banking crisis of March 2023, we do not anticipate any significant financial impact. The vast majority of our funds are in the two largest banks in the United States, as measured by total assets.

Management anticipates providing updated 2023 earnings guidance as part of the June 30, 2023, earnings press release.

On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term


-20-


For

loan. Principal payments of $1.25 million on the nine months ended September 30, 2017,term loan are due on the last day of each fiscal quarter, with a final payment due at the end of the agreement. The 2022 Credit Facilities have a floating interest rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of March 31, 2023, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities includes an expansion feature that provides the Company the opportunity to increase in consolidated service revenuesits revolver and sales was driven by a 14.4% increase at Roto-Rooter and a 2.0% increase at VITAS.  The increase in service revenues at Roto-Rooter was drivenor term loan by an increase in all major service lines. Of Roto-Rooter’s total revenue increase, 49.0% was related to water restoration.  The increase in service revenues at VITAS was primarily a result of Medicare reimbursement rates increasing 1.7%, a 2.7% increase in days of care, offset by acuity mix shift which negatively impacted revenue 2.4% when compared to the prior year period.  Adjusted EBITDA as a percent of revenue increased 130 basis points when compared to the prior year quarter mainly as a result of mix shift in levels of care and improved cost management for high acuity care.  See page 33 for additional VITAS operating metrics.


VITAS expects its full-year 2017 revenue growth, prior to Medicare cap, to be$250.0 million.

We made prepayments totaling $75.0 million in the rangefirst quarter of 2.0%2023, on the $100.0 million term loan. We plan to 3.0%.  Admissions and Average Daily Census in 2017pay the remaining balance of $21.3 million on April 28, 2023. There are estimated to expand approximately 2.0% to 3.0%.  Adjusted EBITDA margin, prior to Medicare cap, is estimated to be 15.0%.  This guidance includes $1.5 million for Medicare cap billing limitations. Roto-Rooter expects full-year 2017 revenue growth of 13.0% to 14.0%.  The revenue estimate is a based upon increased job pricing of approximately 2.0% and continued growth in water restoration services.  Adjusted EBITDA margin for 2017 is estimated in the range of 22.5%.  We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

-16-

Financial Condition
Liquidity and Capital Resources
Material changes in the balance sheet accounts from December 31, 2016 to September 30, 2017 include the following:

A $40.5 million decrease in accounts receivable due mainly to timing of Medicare and Medicaid payments.
A $21.8 million increase in properties plant and equipment mainly due to the purchase of transportation equipment during the quarter.
A $36.2 million increase in net deferred taxesno prepayment penalties associated with amounts recorded for a potential litigation settlement.
A $4.8this repayment. This will reduce the borrowing capacity of the 2022 Credit Facilities from $550.0 million decrease in accounts payable mainly due to timing of payments.
A $12.3 increase in income taxes due to timing of payments.
An $89.6 million increase in accrued legal due to a potential litigation settlement.
A $26.3 million decrease in long-term debt due to payments on our term loan and revolving line of credit.

Net cash provided by operating activities increased $62.6 million mainly as a result of a $22.9 million increase in net income excluding potential litigation settlement and a $19.5 million decrease caused by changes in accounts receivable.  The potential litigation settlement recorded is non-cash at September 30, 2017 and does not impact net cash provided by operating activities.

Significant changes in our accounts receivable balances are typically driven mainly by the timing of payments received from the Federal government at our VITAS subsidiary.  We typically receive a payment in excess of $40.0 million from the Federal government from hospice services every other Friday.  The timing of period end will have a significant impact on the accounts receivable at VITAS.  These changes generally normalize over a two year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

$450.0 million.

We have issued $35.6$45.3 million in standby letters of credit as of September 30, 2017,March 31, 2023, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement.2022 Credit Facilities. As of September 30, 2017,March 31, 2023, we have approximately $309.4$404.7 million of unused lines of credit available and are eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.


We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2022 to March 31, 2023 include the following:

A $14.4 million increase in accounts receivable due to timing of receipts. See discussion below.

A $7.9 million decrease in prepaid income taxes due to timing of payments.

An $11.2 million increase in income tax due to timing of payments.

A $37.2 million decline in accrued compensation due to payment of 2022 bonuses in the first quarter of 2023.

An $8.3 million increase in other current liabilities due mainly to the healthcare worker retention bonus program at VITAS.

A $76.3 million decrease in long-term debt due to repayments.

Net cash provided by operating activities decreased $40.6 million from March 31, 2022 to March 31, 2023. The main drivers of the decrease are a decrease in net income of $10.0 million, and a $33.9 million increase in accounts receivable. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $42.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

Commitments and Contingencies

Collectively, the terms of our credit agreementsthe 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of September 30, 2017March 31, 2023 and anticipate remaining in compliance throughout the foreseeable future.


The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected

We are subject to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware.  Other than as described below with respect to U.S. v. Vitas, it is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or reasonably estimable.

-17-

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiariesclaims in the U.S. District Courtnormal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the Western Districtexistence of Missouri, United States v. VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”).  Prior to that date, the Company received various qui tam lawsuitsregulatory and subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed.  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care serviceslegal actions when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.  The defendants filed a motion to dismiss on September 24, 2013.  On September 30, 2014, the Court denied the motion, except to the extent that claims were filed before July 24, 2002. On November 13, 2014, the government filed a Second Amended Complaint.  The Second Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS.  VITAS filed its Answer to the Second Amended Complaint on August 11, 2015.  Based on recent case developments, including recent mediation discussions with the U.S. Department of Justice, we believe it probable that this matter will be settled, to include payments of $55.8 million after-tax ($90.0 million pretax) including attorneys’ fees.  A final settlement will require the parties to resolve several outstanding issues, and to draft and negotiate definitive documentation.  There can be no assurance that such a final definitive settlement will be reached on these, or other, terms.  For additional procedural history of this litigation, please refer to our prior quarterly and annual filings.  The costs incurred related to U.S. v. Vitas and related regulatory matters were $935,000 and $599,000 for the quarters ended September 30, 2017 and 2016, respectively.  For the nine months ended September 30, 2017 and 2016, the net costs were $5.2 million and $4.1 million respectively.

Net income for the nine months ended September 30, 2017 includes the $55.8 million of after-tax expense ($90 million pre-tax) for the accrual of such potential litigation settlement.  As required by GAAP, the Company accrues for contingent loss claims in its financial statements when it is probablereasonably possible that a liability has been incurred and the amount can be reasonably estimated.

The Company and certain current and former directors and officers are defendantsloss could occur in a case captioned In re Chemed Corp. Shareholder Derivative Litigation, No. 13 Civ. 1854 (LPS) (CJB) (D. Del.), which was consolidated on February 2, 2015.

On February 2, 2015, the Court appointed KBC Asset Management NV the sole lead plaintiff and its counsel, the sole lead and liaison counsel. On March 3, 2015, Lead Plaintiff KBC designated its Complaint as the operative complaint in the consolidated proceedings and defendants renewed a previously filed motion to dismiss those claims and allegations.  The consolidated Complaint named fourteen individual defendants, togetherconnection with the Company as nominal defendant.  The Complaint allegesspecific action. In most instances, we are unable to make a claim for breachreasonable estimate of fiduciary duty against the individual defendants for allegedly permitting the Company to submit false claimsany reasonably possible liability due to the U.S. government.  The Complaint seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.  On May 12, 2016, the Court issued a Memorandum Order granting Chemed’s motion to dismiss, and  dismissing Lead Plaintiff KBC’s Complaint without prejudice to KBC’s opportunity to file within 30 days of the date of the Court’s Order (i.e., by June 13, 2016) an amended Complaint addressing the deficiencies in its duty of loyalty claim.  Lead Plaintiff KBC did not file an amended Complaint within the time specified by the Court.

However, on June 13, 2016, counsel for Chemed shareholder Michael Kvint filed a letter with the Court requesting a two-week extension to file a motion to substitute Mr. Kvint as lead plaintiff, in place of Lead Plaintiff KBC and to file an amended Complaint.  Alternatively, counsel for Mr. Kvint requested that any dismissal of the action be with prejudice to KBC only.  On June 14, 2016, Chemed filed a reply letter with the Court, reserving its rights to oppose any motion filed by Mr. Kvint and, if warranted, to oppose any other actions taken by Mr. Kvint to proceed with the action (including by filing an untimely amended Complaint).  On June 21, 2016, the Court entered an Oral Order providing Mr. Kvint until June 30, 2016 to file a Motion to Substitute and Motion for Leave to File an Amended Complaint.  On that date, Mr. Kvint filed, under seal, a Motion to Substitute Plaintiff and File Amended Complaint, and attached a Proposed Amended Complaint.    Mr. Kvint’s motion was fully briefed by the parties.  On April 25, 2017, Magistrate Judge Burke issued a Report and Recommendation recommending that the Court permit Mr. Kvint to intervene as Lead Plaintiff and grant leave to amend the complaint to replead the duty of loyalty claim only.  On May 16, 2017, Chief Judge Stark signed an Order adopting that Report and Recommendation.  Plaintiff Kvint filed a Corrected Amended Complaint on May 30, 2017.  On September 13, 2017, the Court entered an order dismissing with prejudice the claims against defendants Timothy S, O’Toole and Joel F. Gemunder and permitting Defendants to file a Motion to Dismiss the Corrected Amended Complaint on or before September 29, 2017, with Plaintiff’s Answering to be filed on or before December 1, 2017, and Defendants’ Reply Brief to be filed on or before December 29, 2017.  Defendants filed their Motion to Dismiss timely. As the Company has previously disclosed, the legal fees and costs associated with defending against this lawsuit are presently being paid by insurance. For additional procedural history of this litigation, please refer to our prior quarterly and annual filings.
-18-

Jordan Seper, (“Seper”) a Registered Nurse at VITAS' Inland Empire program from May 12, 2014 to March 21, 2015, filed a lawsuit in San Francisco Superior Court on September 26, 2016.  She alleged VITAS Healthcare Corp of CA (“VITAS CA”) (1) failed to provide minimum wage for all hours worked; (2) failed to provide overtime for all hours worked; (3) failed to provide a second meal period; (4) failed to provide rest breaks; (5) failed to indemnify for necessary expenditures; (6) failed to timely pay wages due at time of separation; and (7) engaged in unfair business practices.  Seper seeks a state-wide class action of current and former non-exempt employees employed with VITAS in California within the four years preceding the filing of the lawsuit.  She seeks court determination that this action may be maintained as a class action for the entire California class and subclasses, designation as class representative, declaratory relief, injunctive relief, damages (including wages for regular or overtime hours allegedly worked but not paid, premium payments for missed meal or rest periods, and unreimbursed expenses), all applicable penalties associated with each claim, pre and post-judgment interest, and attorneys' fees and costs.  Seper served VITAS CA with the lawsuit,  Jordan A. Seper on behalf of herself and others similarly situated v. VITAS Healthcare Corporation of California, a Delaware corporation; VITAS Healthcare Corp of CA, a business entity unknown; and DOES 1 to 100, inclusive; Los Angeles Superior Court Case Number BC 642857 on October 13, 2016.

On November 14, 2016, the Parties filed a Stipulation to transfer the venue of the lawsuit from San Francisco to Los Angeles.  The Los Angeles Superior Court Complex Division accepted transfer of the case on December 6, 2016 and stayed the case.  On December 16, 2016, VITAS CA filed its Answer and served written discovery on Seper.

Jiwan Chhina ("Chhina"), hired by VITAS as a Home Health Aide on February 5, 2002, is currently a Licensed Vocational Nurse for VITAS' San Diego program.  On September 27, 2016, Chhina filed a lawsuit in San Diego Superior Court, alleging (1) failure to pay minimum wage for all hours worked; (2) failure to provide overtime for all hours worked; (3) failure to pay wages for all hours at the regular rate; (4) failure to provide meal periods; (5) failure to provide rest breaks; (6) failure to provide complete and accurate wage statements; (7) failure to pay for all reimbursement expenses; (8) unfair business practices; and (9) violation of the California Private Attorneys General Act.  Chhina seeks to pursue these claims in the form of a state-wide class action of current and former non-exempt employees employed with VITAS in California within the four years preceding the filing of the lawsuit.  He seeks court determination that this action may be maintained as a class action for the entire California class and subclasses, designation as class representative, declaratory relief, injunctive relief, damages (including wages for regular or overtime hours allegedly worked but not paid, premium payments for missed meal or rest periods, and unreimbursed expenses), all applicable penalties associated with each claim, pre-judgment interest, and attorneys' fees and costs.  Chhina served VITAS CA with the lawsuit, Jiwann Chhina v. VITAS Health Services of California, Inc., a California corporation; VITAS Healthcare Corporation of California, a Delaware corporation; VITAS Healthcare Corporation of California, a Delaware corporation dba VITAS Healthcare, Inc.; and DOES 1 to 100, inclusive; San Diego Superior Court Case Number 37-2015-00033978-CU-OE-CTL on November 3, 2016.  On December 1, 2016, VITAS CA filed its Answer and served written discovery on Chhina.

On May 19, 2017, Chere Phillips (a Home Health Aide in Sacramento) and Lady Moore (a former Social Worker in Sacramento) filed a lawsuit against VITAS Healthcare Corporation of California in Sacramento County Superior Court, alleging claims for (1) failure to pay all wages due; (2) failure to authorize and permit rest periods; (3) failure to provide off-duty meal periods; (4) failure to furnish accurate wage statements; (5) unreimbursed business expenses; (6) waiting time penalties; (7) violations of unfair competition law; and (8) violation of the Private Attorney General Act.  The case is captioned: Chere Phillips and Lady Moore v. VITAS Healthcare Corporation of California, Sacramento County Superior Court, Case No. 34-2017-0021-2755.  Plaintiffs sought to pursue these claims in the form of a state-wide class action of current and former non-exempt employees employed with VITAS CA in California within the four years preceding the filing of the lawsuit.  Plaintiffs served VITAS with the lawsuit on June 5, 2017. VITAS CA timely answered the Complaint generally denying the Plaintiffs’ allegations.  The Court has stayed all class discovery in this case pending the resolution of the November 10, 2017 in the Seper and Chhina cases.

There are currently three other lawsuits against VITAS pending in the superior courts of other California counties that contain claims and class periods that substantially overlap with Phillips’ and Moore’s claims.  These are Seper, v. VITAS Healthcare Corp of California et al., filed on September 26, 2016 in Los Angeles County Superior Court BC 642857; Chhina v. VITAS Health Service, Inc. et al., filed on September 27, 2016 in San Diego County Superior Court, 34-2015-00033998 CU_OE_CTL; both described above and Williams v. VITAS Healthcare Corporation of California, filed on May 22, 2017 in Alameda County Superior Court, RG 17853886.

Jazzina Williams’ (a Home Health Aide in Sacramento) lawsuit alleges claims for (1) failure to pay all wages due; (2) failure to authorize and permit rest periods; (3) failure to provide off-duty meal periods; (4) failure to furnish accurate wage statements; (5) unreimbursed business expenses; (6) waiting time penalties; and (7) violations of the Private Attorney General Act.  Williams seeks to pursue these claims in the form of a state-wide class action of current and former non-exempt employees.  Plaintiff served VITAS with the lawsuit on May 31, 2017.  VITAS timely answered the Complaint generally denying Plaintiff’s allegations.  Williams is pursuing discovery of her individual claims and has agreed to a stay of class discovery pending outcome of a November 10, 2017 mediation of the Seper and Chhina cases.  Defendant filed and served each of Plaintiffs Williams, Phillips, and Moore with a Notice of Related Cases on July 19, 2017.  Defendant understands that the Seper and Chhina cases will be effectively consolidated in Los Angeles County Superior court: Chhina will be dismissed as a separate action and joined with Seper through the filing of an amended complaint in Seper in which Chhina is also identified as a named plaintiff.
-19-

The Company is not able to reasonably estimate the probability of loss or range of loss for any of these lawsuits at this time.

The Company intends to defend vigorously against the allegations in each of the above lawsuits.  Regardlessuncertainty of the outcome and stage of anylitigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of the preceding matters, dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity.  Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have acurrent material adverse effect on the Company.legal matters.



-21-


Results of Operations

Three months ended September 30, 2017March 31, 2023 versus 20162022 - Consolidated Results

Our service revenues and sales for the thirdfirst quarter of 20172023 increased 6.3%5.6% versus services and sales revenues for the thirdfirst quarter of 2016.2022. Of this increase, a $6.1an $18.3 million increase was attributable to VITASRoto-Rooter, and $18.8an $11.3 million increase was attributable to Roto-Rooter.VITAS. The following chart shows the components of those changesrevenue by operating segment (in thousands):

Three months ended March 31,

Increase/(Decrease)

2023

2022

Percent

VITAS

Routine homecare

$

267,050 

$

257,636 

3.7 

Continuous care

19,941 

19,578 

1.9 

General inpatient

29,093 

26,570 

9.5 

Other

3,021 

3,007 

0.5 

Subtotal

319,105 

306,791 

4.0 

Medicare cap adjustment

(2,750)

(2,500)

(10.0)

Room and board - net

(2,769)

(2,117)

(30.8)

Implicit price concessions

(3,108)

(2,985)

(4.1)

Net revenue

$

310,478 

$

299,189 

3.8 

Roto-Rooter

Drain cleaning

$

66,489 

$

66,687 

(0.3)

Plumbing

50,453 

47,672 

5.8 

Excavation

59,576 

55,188 

8.0 

Other

193 

165 

17.0 

Subtotal - short term core

176,711 

169,712 

4.1 

Water restoration

50,762 

40,360 

25.8 

Independent contractors

23,300 

21,418 

8.8 

Outside franchisee fees

1,351 

1,317 

2.6 

Other

4,745 

4,191 

13.2 

Gross revenue

256,869 

236,998 

8.4 

Implicit price concessions

(7,190)

(5,638)

(27.5)

Net revenue

249,679 

231,360 

7.9 

Total Revenues

$

560,157 

$

530,549 

5.6 

Days of care at VITAS during the quarters were as follows:

Three months ended March 31,

Increase/(Decrease)

2023

2022

Percent

Routine homecare

1,286,437 

1,258,672 

2.2 

Nursing home

265,429 

248,468 

6.8 

Respite

5,760 

5,368 

7.3 

Subtotal routine homecare and respite

1,557,626 

1,512,508 

3.0 

General inpatient

26,369 

24,587 

7.2 

Continuous care

20,686 

21,082 

(1.9)

Total days of care

1,604,681 

1,558,177 

3.0 

  Increase/(Decrease) 
  Amount  Percent 
VITAS      
Routine homecare $11,217   5.0 
Continuous care  (4,025)  (11.9)
General inpatient  (1,334)  (5.6)
Medicare cap  228   100.0 
Roto-Rooter        
Plumbing  7,262   15.2 
Drain cleaning  1,442   4.1 
Water restoration  9,208   77.2 
Contractor operations  632   6.4 
Other  207   4.2 
Total $24,837   6.3 

The increase in VITAS’service revenues for the third quarterat VITAS is comprised primarily of 2017 versus the third quarter of 2016 was comprised of ana 3.0% increase in days-of-care and a geographically weighted average net Medicare reimbursement rate increasingincrease of approximately 1.3%2.9%, a 2.8% increase in days of carepartially offset by acuity200-basis points as a result of CMS reimplementing the 2.0% sequestration cut that was suspended at the start of the pandemic in 2020. Acuity mix shift which negatively impacted revenue 2.2%had minimal impact in the quarter when compared to the prior year period.


Daysrevenue and level-of-care mix. The combination of care during the quarter ended September 30 were as follows:
 Days of Care Increase/(Decrease)
 2017 2016 Percent
      
Routine homecare 1,458,153  1,407,623  3.6
Continuous care 41,237  46,582  (11.5)
General inpatient 32,567  36,241  (10.1)
Total days of care 1,531,957  1,490,446  2.8

Over 90% of VITAS’ service revenues for the period were from Medicare cap and Medicaid.

other contra revenue changes negatively impacted revenue growth by 10-basis points.

The increase in plumbing revenues for the thirdfirst quarter of 20172023 versus 20162022 is attributable to a 14.2% increase in price and service mix shift as well as a 1.0% increase in job count.  Drain cleaning revenues for the third quarter of 2017 versus 2016 reflect a 6.2%13.0% increase in price and service mix shift offset by a 2.1%7.2% decrease in job count. WaterExcavation and water restoration for the third quarter of 2017 versus 2016 increased 77.2%jobs are generally sold as a result of continued expansion of this service offering includinginitial

-22-


calls from customers regarding drain cleaning issues. As a 38.0%result, the 8.0% increase in numberexcavation revenue and the 25.8% increase in water restoration revenue are mainly a function of jobs performed.the numbers and size of drain cleaning issues we encounter on a quarterly basis. Independent Contractor operationsrevenue increased 6.4%8.8% due mainly due to theirincreased expansion into water restoration.

-20-

The consolidated gross margin was 31.0%33.8% in the thirdfirst quarter of 20172023 as compared with 28.3%36.6% in the thirdfirst quarter of 2016.2022. On a segment basis, VITAS’ gross margin was 23.1%18.3% in the thirdfirst quarter of 20172023 as compared with 20.7%24.0%, in the thirdfirst quarter of 2016.2022. The increasedecrease in VITAS gross margin at VITAS is mostly the result of labor and ancillary cost management.the $10.9 million expense recorded in the first quarter of 2023 for the licensed healthcare worker retention bonus program. The Roto-Rooter segment’s gross margin was 48.7%53.1% for the thirdfirst quarter of 20172023 as compared with 47.8%52.8% in the thirdfirst quarter of 2016.  The increase in Roto-Rooter gross margin is the result mainly of higher revenues, particularly in water restoration, with relatively low increase in branch level fixed costs.


2022.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Three months ended March 31,

2023

2022

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts

$

97,902 

$

92,578 

Impact of market value adjustments related to assets held in deferred compensation trusts

(321)

(3,934)

Long-term incentive compensation

2,514 

1,310 

Total SG&A expenses

$

100,095 

$

89,954 


  Three months ended September 30, 
  2017  2016 
SG&A expenses before market value adjustments of deferred compensation      
plans, long-term incentive compensation, and OIG investigation expenses $63,463  $56,475 
Impact of market value adjustments related to assets held in deferred        
compensation trusts  1,417   1,656 
Long-term incentive compensation  1,104   643 
Expenses related to OIG investigation  935   599 
Total SG&A expenses $66,919  $59,373 

SG&A expenses before long-term incentive compensation expenses related to OIG investigation and the impact of market value adjustments related to assets held in deferred compensation trusts for the thirdfirst quarter of 20172023 were up 12.4%5.8% when compared to the thirdfirst quarter of 2016.2022. This increase was mainly a result of the increase in variable selling and general administrative expenses caused by increased revenue, particularly in the Roto-Rooter segment, increased advertising expenseand overall inflation-related cost increases, including salary at Roto-Rooter and normal salary increases in 2017.

During the third quarter of 2017, a credit of $371,000 was recorded due to the recovery of previously recognized expenses related to the closure of the programs in one state at Vitas.  There were no otherboth operating expenses recorded in the third quarter of 2016.

units.

Other income/(expense) -/income – net comprise (in thousands):

Three months ended March 31,

2023

2022

Market value adjustment on assets held in deferred compensation trusts

$

(321)

$

(3,934)

Interest income

150 

73 

Other

68 

(1)

Total expense - net

$

(103)

$

(3,862)

  Three months ended September 30, 
  2017  2016 
Market value adjustment on assets held in      
deferred compensation trusts $1,417  $1,656 
Loss on disposal of property and equipment  (146)  (134)
Interest income  51   119 
Other  1   (1)
Total other income/(expense) - net $1,323  $1,640 

Our effective income tax rate was 34.7% in the third quarter of 2017 compared to 38.3% during the third quarter of 2016.  The change in the effective income tax ratereconciliation is a result of the adoption of ASU No. 2016-09 – Compensation – Stock Compensation in 2017 which requires that the excess tax benefits from stock based compensation now be recorded in the income tax provision on the statements of income.  Excluding the adoption of the ASU, our effective income tax rate is 38.0%.as follows (in thousands):

Three months ended March 31,

2023

2022

Income tax provision calculated at the statutory federal rate

$

14,945 

$

17,787 

Stock compensation tax benefits

(1,650)

(1,441)

State and local income taxes

2,940 

3,241 

Other--net

809 

946 

Income tax provision

$

17,044 

$

20,533 

Effective tax rate

23.9 

%

24.2 

%



-21-

-23-



Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

Three months ended March 31,

2023

2022

VITAS

Licensed healthcare worker retention bonus

$

(8,144)

$

-

Direct costs related to COVID-19

-

(292)

Roto-Rooter

Amortization of reacquired franchise agreements

(1,729)

(1,729)

Litigation settlements

(1,290)

-

Direct costs related to COVID-19

-

(706)

Corporate

Stock option expense

(7,010)

(6,166)

Long-term incentive compensation

(2,223)

(1,159)

Excess tax benefits on stock compensation

1,650 

1,441 

Total

$

(18,746)

$

(8,611)

  Three months ended September 30, 
  2017  2016 
VITAS      
Expenses related to OIG investigation $(578) $(370)
Program closure income  223   - 
Medicare cap sequestration adjustment  -   (141)
Corporate        
Excess tax benefits on stock compensation  1,783   - 
Stock option expense  (1,064)  (897)
Long-term incentive compensation  (699)  (406)
Total $(335) $(1,814)

Three months ended September 30, 2017March 31, 2023 versus 20162022 - Segment Results


The change in net

Net income/(loss) for the thirdfirst quarter of 20172023 versus the thirdfirst quarter of 2016 is due to2022 by segment (in thousands):

Three months ended March 31,

2023

2022

VITAS

$

24,764 

$

36,481 

Roto-Rooter

47,653 

43,937 

Corporate

(18,296)

(16,249)

$

54,121 

$

64,169 


  Increase/(Decrease) 
  Amount  Percent 
VITAS $5,551   26.6 
Roto-Rooter  3,179   24.7 
Corporate  (122)  (1.8)
  8,608   32.1 

VITAS’ after-tax earnings were positively impacteddecreased primarily due to the $8.1 million in 2017after-tax expense related to VITAS’ licensed healthcare worker retention bonus program, as well as the reimplementation of the 2.0% sequestration cut that was suspended at the start of the pandemic in 2020, in the first quarter of 2023 when compared to 2016 by a $6.1 million increase in revenue and a $2.3 million decrease in costthe first quarter of services provided and goods sold.2022. After-tax earnings as a percent of revenue at VITAS in the thirdfirst quarter of 2017 were 9.2%, an increase of 1.8% over2023 was 8.0% as compared to 12.2% in the thirdfirst quarter of 2016.


2022.

Roto-Rooter’s net income was positively impacted in 2017the first quarter of 2023 compared to 2016the first quarter of 2022 primarily by a $9.2 million revenue increase in Roto-Rooter’s water restoration line of business and a $7.3 million increase in plumbinghigher revenue. After-tax earnings as a percent of revenue at Roto-Rooter in the thirdfirst quarter of 20172023 was 12.5%19.1%, as compared to 11.7%19.0% in the thirdfirst quarter of 2016.


Results of Operations
Nine months ended September 30, 2017 versus 2016 - Consolidated Results
Our service revenues and sales2022.

After-tax Corporate expenses for the first nine monthsquarter of 20172023 increased 5.5% versus services and sales revenues for the first nine months of 2016.  Of this increase, a $16.9 million increase was attributable to VITAS and $48.1 million increase was attributable to Roto-Rooter.  The following chart shows the components of those changes (in thousands):


  Increase/(Decrease) 
  Amount  Percent 
VITAS      
Routine homecare $33,882   5.1 
Continuous care  (11,600)  (10.9)
General inpatient  (5,417)  (7.3)
Medicare cap  (19)  (8.3)
Roto-Rooter        
Plumbing  16,852   11.6 
Drain cleaning  3,454   3.2 
Water restoration  23,597   64.6 
Contractor operations  3,180   10.8 
Other  1,033   6.9 
Total $64,962   5.5 
-22-

The increase in VITAS’ revenues for the first nine months of 2017 versus the first nine months of 2016 was comprised of an average net Medicare reimbursement rate increasing approximately 1.3%, a 2.7% increase in days of care offset by acuity mix shift which negatively impacted revenue12.6% when compared to the prior year period.

Days of care during the nine months ended September 30 were as follows:
 Days of Care Increase/(Decrease)
 2017 2016 Percent
      
Routine homecare 4,256,541  4,109,775  3.6
Continuous care 129,762  145,327  (10.7)
General inpatient 97,803  111,323  (12.1)
Total days of care 4,484,106  4,366,425  2.7

Over 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the first nine months of 2017 versus 2016 is attributable primarily to service mix shift as well as a 0.6% increase in job count.  Drain cleaning revenues for the first nine months of 2017 versus 2016 reflect a 5.3% increase in price and service mix shift offset by a 2.1% decrease in job count.  Water restoration for the first nine months of 2017 versus 2016 increased 64.6% as a result of continued expansion of this service offering including a 32.6% increase in jobs performed.  Contractor operations increased 10.8% mainly2022 due to their expansion into water restoration.

The consolidated gross margin was 30.6% in the first nine months of 2017 as compared with 28.7% in the first nine months of 2016.  On a segment basis, VITAS’ gross margin was 22.5% in the first nine months of 2017 as compared with 21.1%, in the first nine months of 2016.  The increase in VITAS’ gross margin is the result of mix shift to higher margin care, labor and ancillary cost management.  The Roto-Rooter segment’s gross margin was 48.9% for the first nine months of 2017 compared with 48.0% in the first nine months of 2016.  The increase in the Roto-Rooter gross margin is the result mainly of higher revenues, particularly in water restoration, with relatively low increase in branch level fixed costs.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

  Nine months ended September 30, 
  2017  2016 
SG&A expenses before market value adjustments of deferred compensation      
plans, long-term incentive compensation, and OIG investigation expenses $191,213  $174,183 
Impact of market value adjustments related to assets held in deferred        
compensation trusts  5,619   1,857 
Expenses related to OIG investigation  5,178   4,105 
Long-term incentive compensation  3,021   901 
Total SG&A expenses $205,031  $181,046 

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market value adjustments related to assets held in deferred compensation trusts for the first nine months of 2017 were up 9.8% when compared to the first nine months of 2016. This increase was mainly a result of the increase in variable expenses caused by increased revenue, particularly in the in the Roto-Rooter segment, increased advertising expense at Roto-Rooter and normal salary increases in 2017.
Other operating expenses were $91.1 million during the first nine months of 2017 related to a $90.0 million potential litigation settlement and $1.1 million related to the closure of the programs in one state at Vitas.  During the first nine months of 2016, the Company recorded $4.5 million related to early retirement expenses.

-23-

Other income - net comprise (in thousands):

  Nine months ended September 30, 
  2017  2016 
Market value adjustment on assets held in      
deferred compensation trusts $5,619  $1,857 
Loss on disposal of property and equipment  (481)  (224)
Interest income  297   301 
Other  4   (1)
Total other income - net $5,439  $1,933 

Our effective income tax rate was 25.8% in the first nine months of 2017 compared to 38.6% during the first nine months of 2016.  The change in the effective income tax rate is due to the adoption of ASU No. 2016-09 – Compensation – Stock Compensation which requires that the excess tax benefits from stock based compensation now be recorded in the income tax provision on the statements of income.  Excluding the impact of the ASU, our effective income tax rate for the first nine months of 2017 was 39.6%.

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):
  Nine Months Ended September 30, 
  2017  2016 
VITAS      
Potential litigation settlement $(55,800) $- 
Expenses related to OIG investigation  (3,198)  (2,535)
Program closure expenses  (675)  - 
Medicare cap sequestration adjustment  (65)  (141)
Early retirement expenses  -   (2,840)
Roto-Rooter        
Expenses related to litigation settlements  (129)  (27)
Corporate        
Excess tax benefits on stock compensation  8,121   - 
Stock option expense  (4,892)  (3,958)
Long-term incentive compensation  (1,911)  (570)
Total $(58,549) $(10,071)

Nine months ended September 30, 2017 versus 2016 - Segment Results

The change in net income/(loss) for the first nine months of 2017 versus the first nine months of 2016 is due to (in thousands):
  Increase/(Decrease) 
  Amount  Percent 
VITAS $(43,741)  (74.7)
Roto-Rooter  8,500   21.7 
Corporate  2,312   10.9 
  (32,929)  (43.0)

VITAS’ 2017 after-tax earnings were impacted in 2017 when compared to 2016 by a $55.8 million (after-tax) potential ligation settlement offset by a $16.8$1.9 million increase in revenue and a $1.2 million decrease in cost of services provided and goods sold.
stock-based compensation.


-24-

-24-



Roto-Rooter’s net income was positively impacted in 2017 compared to 2016 primarily by a $23.6 million revenue increase in Roto-Rooter’s water restoration line of business, a $16.9 million increase in plumbing revenue and a $7.7 million increase in all other revenue types.  After-tax earnings as a percent of revenue at Roto-Rooter in 2017 were 12.5% as compared to 11.7% in 2016.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(in thousands)(unaudited)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

2023 (a)

                         

                         

                         

                         

Service revenues and sales

$

310,478 

$

249,679 

$

-

$

560,157 

Cost of services provided and goods sold

253,654 

117,051 

-

370,705 

Selling, general and administrative expenses

23,336 

60,813 

15,946 

100,095 

Depreciation

4,958 

7,312 

16 

12,286 

Amortization

26 

2,487 

-

2,513 

Other operating expense

12 

1,727 

-

1,739 

Total costs and expenses

281,986 

189,390 

15,962 

487,338 

Income/(loss) from operations

28,492 

60,289 

(15,962)

72,819 

Interest expense

(50)

(133)

(1,368)

(1,551)

Intercompany interest income/(expense)

4,648 

2,743 

(7,391)

-

Other (expense)/ income—net

189 

29 

(321)

(103)

Income/(expense) before income taxes

33,279 

62,928 

(25,042)

71,165 

Income taxes

(8,515)

(15,275)

6,746 

(17,044)

Net income/(loss)

$

24,764 

$

47,653 

$

(18,296)

$

54,121 

(a) The following amounts are included in net income (in thousands):

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

Pretax benefit/(cost):

Licensed healthcare worker retention bonus

$

(10,916)

$

-

$

-

$

(10,916)

Stock option expense

-

-

(8,482)

(8,482)

Long-term incentive compensation

-

-

(2,514)

(2,514)

Amortization of reacquired franchise agreements

-

(2,352)

-

(2,352)

Litigation settlements

-

(1,756)

-

(1,756)

Total

$

(10,916)

$

(4,108)

$

(10,996)

$

(26,020)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

After-tax benefit/(cost):

Licensed healthcare worker retention bonus

$

(8,144)

$

-

$

-

$

(8,144)

Stock option expense

-

-

(7,010)

(7,010)

Long-term incentive compensation

-

-

(2,223)

(2,223)

Amortization of reacquired franchise agreements

-

(1,729)

-

(1,729)

Litigation settlements

-

(1,290)

-

(1,290)

Excess tax benefits on stock compensation

-

-

1,650 

1,650 

Total

$

(8,144)

$

(3,019)

$

(7,583)

$

(18,746)


The improvement at Corporate is due mainly to the impact of the adoption of ASU 2016-09 which positively impacted the Company’s tax provision by approximately $8.1 million which is partially offset by higher stock based compensation expenses.


-25-

-25-



CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED MARCH 31, 2022

(in thousands)(unaudited)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

2022 (a)

                         

                         

                         

                         

Service revenues and sales

$

299,189 

$

231,360 

$

-

$

530,549 

Cost of services provided and goods sold

227,240 

109,312 

-

336,552 

Selling, general and administrative expenses

22,453 

56,954 

10,547 

89,954 

Depreciation

5,551 

6,569 

18 

12,138 

Amortization

24 

2,494 

-

2,518 

Other operating expense/(income)

(148)

161 

-

13 

Total costs and expenses

255,120 

175,490 

10,565 

441,175 

Income/(loss) from operations

44,069 

55,870 

(10,565)

89,374 

Interest expense

(52)

(115)

(643)

(810)

Intercompany interest income/(expense)

4,656 

2,176 

(6,832)

-

Other (expense)/income—net

37 

35 

(3,934)

(3,862)

Income/(expense) before income taxes

48,710 

57,966 

(21,974)

84,702 

Income taxes

(12,229)

(14,029)

5,725 

(20,533)

Net income/(loss)

$

36,481 

$

43,937 

$

(16,249)

$

64,169 

(a) The following amounts are included in net income (in thousands):

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

Pretax benefit/(cost):

Stock option expense

$

-

$

$

(7,451)

$

(7,451)

Amortization of reacquired franchise agreements

-

(2,352)

-

(2,352)

Direct costs related to COVID-19

(391)

(961)

-

(1,352)

Long-term incentive compensation

-

-

(1,310)

(1,310)

Total

$

(391)

$

(3,313)

$

(8,761)

$

(12,465)

Chemed

VITAS

Roto-Rooter

Corporate

Consolidated

After-tax benefit/(cost):

Stock option expense

$

-

$

-

$

(6,166)

$

(6,166)

Amortization of reacquired franchise agreements

-

(1,729)

-

(1,729)

Long-term incentive compensation

-

-

(1,159)

(1,159)

Direct costs related to COVID-19

(292)

(706)

-

(998)

Excess tax benefits on stock compensation

-

-

1,441 

1,441 

Total

$

(292)

$

(2,435)

$

(5,884)

$

(8,611)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES 
CONSOLIDATING STATEMENT OF INCOME 
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017 
(in thousands)(unaudited) 
           
         Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
2017 (a)            
Service revenues and sales $288,951  $128,493  $-  $417,444 
Cost of services provided and goods sold  222,119   65,928   -   288,047 
Selling, general and administrative expenses  23,783   33,694   9,442   66,919 
Depreciation  4,529   4,268   22   8,819 
Amortization  -   33   -   33 
Other operating expenses  (371)  -   -   (371)
Total costs and expenses  250,060   103,923   9,464   363,447 
Income/(loss) from operations  38,891   24,570   (9,464)  53,997 
Interest expense  (53)  (73)  (922)  (1,048)
Intercompany interest income/(expense)  2,950   1,378   (4,328)  - 
Other income/(expense)—net  (86)  (8)  1,417   1,323 
Income/(expense) before income taxes  41,702   25,867   (13,297)  54,272 
Income taxes  (15,248)  (9,833)  6,246   (18,835)
Net income/(loss) $26,454  $16,034  $(7,051) $35,437 
                 
(a) The following amounts are included in net income (in thousands):                
              Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
Pretax benefit/(cost):                
Stock option expense $-  $-  $(1,683) $(1,683)
Long-term incentive compensation  -   -   (1,104)  (1,104)
Program closure expenses  371   -   -   371 
Expenses related to OIG investigation  (935)  -   -   (935)
Total $(564) $-  $(2,787) $(3,351)
                 
              Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
After-tax benefit/(cost):                
Stock option expense $-  $-  $(1,064) $(1,064)
Long-term incentive compensation  -   -   (699)  (699)
Program closure expenses  223   -   -   223 
Expenses related to OIG investigation  (578)  -   -   (578)
Excess tax benefits on stock compensation  -   -   1,783   1,783 
Total $(355) $-  $20  $(335)


-26-

-26-




CHEMED CORPORATION AND SUBSIDIARY COMPANIES 
CONSOLIDATING STATEMENT OF INCOME 
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2016 
(in thousands)(unaudited) 
           
         Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
2016 (a)            
Service revenues and sales $282,865  $109,742  $-  $392,607 
Cost of services provided and goods sold  224,410   57,248   -   281,658 
Selling, general and administrative expenses  21,775   28,635   8,963   59,373 
Depreciation  4,751   3,731   132   8,614 
Amortization  14   77   -   91 
Total costs and expenses  250,950   89,691   9,095   349,736 
Income/(loss) from operations  31,915   20,051   (9,095)  42,871 
Interest expense  (59)  (78)  (881)  (1,018)
Intercompany interest income/(expense)  1,810   800   (2,610)  - 
Other income/(expense)—net  (1)  (14)  1,655   1,640 
Income/(expense) before income taxes  33,665   20,759   (10,931)  43,493 
Income taxes  (12,762)  (7,904)  4,002   (16,664)
Net income/(loss) $20,903  $12,855  $(6,929) $26,829 
                 
(a) The following amounts are included in net income (in thousands):                
              Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
Pretax benefit/(cost):                
Stock option expense $-  $-  $(1,419) $(1,419)
Long-term incentive compensation  -   -   (643)  (643)
Medicare cap sequestration adjustment  (228)  -   -   (228)
Expenses related to OIG investigation  (599)  -   -   (599)
Total $(827) $-  $(2,062) $(2,889)
                 
              Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
After-tax benefit/(cost):                
Stock option expense $-  $-  $(897) $(897)
Long-term incentive compensation  -   -   (406)  (406)
Medicare cap sequestration adjustment  (141)  -   -   (141)
Expenses related to OIG investigation  (370)  -   -   (370)
Total $(511) $-  $(1,303) $(1,814)

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

Chemed Corporation and Subsidiary Companies

(in thousands)

Chemed

For the three months ended March 31, 2023

VITAS

Roto-Rooter

Corporate

Consolidated

                         

                         

                         

Net income/(loss)

$

24,764 

$

47,653 

$

(18,296)

$

54,121 

Add/(deduct):

Interest expense

50 

133 

1,368 

1,551 

Income taxes

8,515 

15,275 

(6,746)

17,044 

Depreciation

4,958 

7,312 

16 

12,286 

Amortization

26 

2,487 

-

2,513 

EBITDA

38,313 

72,860 

(23,658)

87,515 

Add/(deduct):

Intercompany interest expense/(income)

(4,648)

(2,743)

7,391 

-

Interest income

(121)

(29)

-

(150)

Licensed healthcare retention bonus

10,916 

-

-

10,916 

Stock option expense

-

-

8,482 

8,482 

Long-term incentive compensation

-

-

2,514 

2,514 

Litigation settlements

-

1,756 

-

1,756 

Adjusted EBITDA

$

44,460 

$

71,844 

$

(5,271)

$

111,033 

Chemed

For the three months ended March 31, 2022

VITAS

Roto-Rooter

Corporate

Consolidated

Net income/(loss)

$

36,481 

$

43,937 

$

(16,249)

$

64,169 

Add/(deduct):

Interest expense

52 

115 

643 

810 

Income taxes

12,229 

14,029 

(5,725)

20,533 

Depreciation

5,551 

6,569 

18 

12,138 

Amortization

24 

2,494 

-

2,518 

EBITDA

54,337 

67,144 

(21,313)

100,168 

Add/(deduct):

Intercompany interest expense/(income)

(4,656)

(2,176)

6,832 

-

Interest income

(37)

(36)

-

(73)

Stock option expense

-

-

7,451 

7,451 

Direct costs related to COVID-19

391 

961 

-

1,352 

Long-term incentive compensation

-

-

1,310 

1,310 

Adjusted EBITDA

$

50,035 

$

65,893 

$

(5,720)

$

110,208 


-27-

-27-



CHEMED CORPORATION AND SUBSIDIARY COMPANIES 
CONSOLIDATING STATEMENT OF INCOME 
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017 
(in thousands)(unaudited) 
           
         Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
2017 (a)            
Service revenues and sales $855,977  $382,390  $-  $1,238,367 
Cost of services provided and goods sold  663,565   195,474   -   859,039 
Selling, general and administrative expenses  72,608   100,917   31,506   205,031 
Depreciation  14,048   12,322   175   26,545 
Amortization  14   97   -   111 
Other operating expenses  91,138   -   -   91,138 
Total costs and expenses  841,373   308,810   31,681   1,181,864 
Income/(loss) from operations  14,604   73,580   (31,681)  56,503 
Interest expense  (161)  (259)  (2,744)  (3,164)
Intercompany interest income/(expense)  8,478   4,035   (12,513)  - 
Other income/(expense)—net  (95)  (85)  5,619   5,439 
Income/(expense) before income taxes  22,826   77,271   (41,319)  58,778 
Income taxes  (8,029)  (29,555)  22,431   (15,153)
Net income/(loss) $14,797  $47,716  $(18,888) $43,625 
                 
                 
(a) The following amounts are included in net income (in thousands):         
              Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
Pretax benefit/(cost):                
Potential litigation settlement $(90,000) $-  $-  $(90,000)
Medicare cap sequestration adjustments  (105)  -   -   (105)
Stock option expense  -   -   (7,738)  (7,738)
Long-term incentive compensation  -   -   (3,021)  (3,021)
Expenses related to litigation settlements  -   (213)  -   (213)
Program closure expenses  (1,138)  -   -   (1,138)
Expenses related to OIG investigation  (5,178)  -   -   (5,178)
Total $(96,421) $(213) $(10,759) $(107,393)
                 
              Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
After-tax benefit/(cost):                
Potential litigation settlement $(55,800) $-  $-  $(55,800)
Medicare cap sequestration adjustments  (65)  -   -   (65)
Stock option expense  -   -   (4,892)  (4,892)
Long-term incentive compensation  -   -   (1,911)  (1,911)
Expenses related to litigation settlements  -   (129)  -   (129)
Program closure expenses  (675)  -   -   (675)
Expenses related to OIG investigation  (3,198)  -   -   (3,198)
Excess tax benefits on stock compensation  -   -   8,121   8,121 
Total $(59,738) $(129) $1,318  $(58,549)

RECONCILIATION OF ADJUSTED NET INCOME

(in thousands, except per share data)(unaudited)

Three Months Ended March 31,

2023

2022

Net income as reported

$

54,121 

$

64,169 

Add/(deduct) pre-tax cost of:

Licensed healthcare worker retention bonus

10,916 

-

Stock option expense

8,482 

7,451 

Long-term incentive compensation

2,514 

1,310 

Amortization of reacquired franchise agreements

2,352 

2,352 

Litigation settlements

1,756 

-

Direct costs related to COVID-19

-

1,352 

Add/(deduct) tax impacts:

Tax impact of the above pre-tax adjustments (1)

(5,624)

(2,413)

Excess tax benefits on stock compensation

(1,650)

(1,441)

Adjusted net income

$

72,867 

$

72,780 

Diluted Earnings Per Share As Reported

Net income

$

3.58 

$

4.22 

Average number of shares outstanding

15,110 

15,192 

Adjusted Diluted Earnings Per Share

Adjusted net income

$

4.82 

$

4.79 

Adjusted average number of shares outstanding

15,110 

15,192 

(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.


-28-

-28-




CHEMED CORPORATION AND SUBSIDIARY COMPANIES

OPERATING STATISTICS FOR VITAS SEGMENT

(unaudited)

Three Months Ended March 31,

OPERATING STATISTICS

2023

2022

Net revenue ($000)

Homecare

$

267,050

$

257,636

Inpatient

29,093

26,570

Continuous care

19,941

19,578

Other

3,021

3,007

Subtotal

$

319,105

$

306,791

Room and board, net

(2,769)

(2,117)

Contractual allowances

(3,108)

(2,985)

Medicare cap allowance

(2,750)

(2,500)

Total

$

310,478

$

299,189

Net revenue as a percent of total before Medicare cap allowances

Homecare

83.7

%

84.0

%

Inpatient

9.1

8.7

Continuous care

6.2

6.4

Other

1.0

0.9

Subtotal

100.0

100.0

Room and board, net

(0.8)

(0.7)

Contractual allowances

(1.0)

(1.0)

Medicare cap allowance

(0.9)

(0.8)

Total

97.3

%

97.5

%

Days of care

Homecare

1,286,437

1,258,672

Nursing home

265,429

248,468

Respite

5,760

5,368

Subtotal routine homecare and respite

1,557,626

1,512,508

Inpatient

26,369

24,587

Continuous care

20,686

21,082

Total

1,604,681

1,558,177

Number of days in relevant time period

90

90

Average daily census (days)

Homecare

14,294

13,985

Nursing home

2,949

2,761

Respite

64

60

Subtotal routine homecare and respite

17,307

16,806

Inpatient

293

273

Continuous care

230

234

Total

17,830

17,313

Total Admissions

16,179

16,530

Total Discharges

15,405

16,862

Average length of stay (days)

99.9

104.8

Median length of stay (days)

15.0

14.0

ADC by major diagnosis

Cerebro

41.8

%

36.7

%

Neurological

19.3

22.9

Cancer

10.5

11.1

Cardio

16.0

15.9

Respiratory

7.3

7.4

Other

5.1

6.0

Total

100.0

%

100.0

%

Admissions by major diagnosis

Cerebro

26.4

22.9

%

Neurological

10.7

12.9

Cancer

24.7

24.9

Cardio

16.2

14.1

Respiratory

10.9

11.1

Other

11.1

14.1

Total

100.0

%

100.0

%

Estimated uncollectible accounts as a percent of revenues

1.0

%

1.0

%

Accounts receivable --

Days of revenue outstanding- excluding unapplied Medicare payments

34.7

33.6

Days of revenue outstanding- including unapplied Medicare payments

29.2

23.9

CHEMED CORPORATION AND SUBSIDIARY COMPANIES 
CONSOLIDATING STATEMENT OF INCOME 
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2016 
(in thousands)(unaudited) 
           
         Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
2016 (a)            
Service revenues and sales $839,131  $334,274  $-  $1,173,405 
Cost of services provided and goods sold  662,371   173,977   -   836,348 
Selling, general and administrative expenses  69,197   87,890   23,959   181,046 
Depreciation  14,346   10,860   413   25,619 
Amortization  41   233   -   274 
Other operating expenses  4,491   -   -   4,491 
Total costs and expenses  750,446   272,960   24,372   1,047,778 
Income/(loss) from operations  88,685   61,314   (24,372)  125,627 
Interest expense  (176)  (264)  (2,391)  (2,831)
Intercompany interest income/(expense)  5,840   2,614   (8,454)  - 
Other income/(expense)—net  76   (2)  1,859   1,933 
Income/(expense) before income taxes  94,425   63,662   (33,358)  124,729 
Income taxes  (35,887)  (24,446)  12,158   (48,175)
Net income/(loss) $58,538  $39,216  $(21,200) $76,554 
                 
                 
(a) The following amounts are included in net income (in thousands):         
              Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
Pretax benefit/(cost):                
Stock option expense $-  $-  $(6,259) $(6,259)
Medicare cap sequestration adjustment  (228)  -   -   (228)
Long-term incentive compensation  -   -   (901)  (901)
Early retirement expenses  (4,491)  -   -   (4,491)
Expenses related to litigation settlements  -   (44)  -   (44)
Expenses related to OIG investigation  (4,105)  -   -   (4,105)
Total $(8,824) $(44) $(7,160) $(16,028)
                 
              Chemed 
  VITAS  Roto-Rooter  Corporate  Consolidated 
After-tax benefit/(cost):                
Stock option expense $-  $-  $(3,958) $(3,958)
Medicare cap sequestration adjustment  (141)  -   -   (141)
Long-term incentive compensation  -   -   (570)  (570)
Early retirement expenses  (2,840)  -   -   (2,840)
Expenses related to litigation settlements  -   (27)  -   (27)
Expenses related to OIG investigation  (2,535)  -   -   (2,535)
Total $(5,516) $(27) $(4,528) $(10,071)


-29-

-29-




Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA 
             
Chemed Corporation and Subsidiary Companies    
(in thousands)          Chemed 
For the three months ended September 30, 2017 VITAS  Roto-Rooter  Corporate  Consolidated 
             
Net income/(loss) $26,454  $16,034  $(7,051) $35,437 
Add/(deduct):                
Interest expense  53   73   922   1,048 
Income taxes  15,248   9,833   (6,246)  18,835 
Depreciation  4,529   4,268   22   8,819 
Amortization  -   33   -   33 
EBITDA  46,284   30,241   (12,353)  64,172 
Add/(deduct):                
Intercompany interest expense/(income)  (2,950)  (1,378)  4,328   - 
Interest income  (48)  (4)  -   (52)
Expenses related to OIG investigation  935   -   -   935 
Program closure expenses  (371)  -   -   (371)
Amortization of stock awards  72   67   156   295 
Advertising cost adjustment  -   (162)  -   (162)
Stock option expense  -   -   1,683   1,683 
Long-term incentive compensation  -   -   1,104   1,104 
Adjusted EBITDA $43,922  $28,764  $(5,082) $67,604 
                 
              Chemed 
For the three months ended September 30, 2016 VITAS  Roto-Rooter  Corporate  Consolidated 
                 
Net income/(loss) $20,903  $12,855  $(6,929) $26,829 
Add/(deduct):                
Interest expense  59   78   881   1,018 
Income taxes  12,762   7,904   (4,002)  16,664 
Depreciation  4,751   3,731   132   8,614 
Amortization  14   77   -   91 
EBITDA  38,489   24,645   (9,918)  53,216 
Add/(deduct):                
Intercompany interest expense/(income)  (1,810)  (800)  2,610   - 
Interest income  (108)  (11)  -   (119)
Expenses related to litigation settlements  1,149   -   -   1,149 
Expenses related to OIG investigation  599   -   -   599 
Medicare cap sequestration adjustment  228   -   -   228 
Amortization of stock awards  85   76   279   440 
Advertising cost adjustment  -   (188)  -   (188)
Stock option expense  -   -   1,419   1,419 
Long-term incentive compensation  -   -   643   643 
Adjusted EBITDA $38,632  $23,722  $(4,967) $57,387 
-30-


Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA 
             
Chemed Corporation and Subsidiary Companies    
(in thousands)          Chemed 
For the nine months ended September 30, 2017 VITAS  Roto-Rooter  Corporate  Consolidated 
             
Net income/(loss) $14,797  $47,716  $(18,888) $43,625 
Add/(deduct):                
Interest expense  161   259   2,744   3,164 
Income taxes  8,029   29,555   (22,431)  15,153 
Depreciation  14,048   12,322   175   26,545 
Amortization  14   97   -   111 
EBITDA  37,049   89,949   (38,400)  88,598 
Add/(deduct):                
Intercompany interest expense/(income)  (8,478)  (4,035)  12,513   - 
Interest income  (267)  (29)  -   (296)
Potential litigation settlement  90,000   -   -   90,000 
Medicare cap sequestration adjustment  105   -   -   105 
Program closure expenses  1,138   -   -   1,138 
Expenses related to OIG investigation  5,178   -   -   5,178 
Stock award amortization  220   203   510   933 
Advertising cost adjustment  -   (707)  -   (707)
Expenses related to litigation settlements  -   213   -   213 
Stock option expense  -   -   7,738   7,738 
Long-term incentive compensation  -   -   3,021   3,021 
Adjusted EBITDA $124,945  $85,594  $(14,618) $195,921 
                 
              Chemed 
For the nine months ended September 30, 2016 VITAS  Roto-Rooter  Corporate  Consolidated 
                 
Net income/(loss) $58,538  $39,216  $(21,200) $76,554 
Add/(deduct):                
Interest expense  176   264   2,391   2,831 
Income taxes  35,887   24,446   (12,158)  48,175 
Depreciation  14,346   10,860   413   25,619 
Amortization  41   233   -   274 
EBITDA  108,988   75,019   (30,554)  153,453 
Add/(deduct):                
Intercompany interest expense/(income)  (5,840)  (2,614)  8,454   - 
Interest income  (256)  (45)  -   (301)
Early retirement expenses  4,491   -   -   4,491 
Expenses related to OIG investigation  4,105   -   -   4,105 
Stock award amortization  302   230   883   1,415 
Medicare cap sequestration adjustment  228   -   -   228 
Expenses related to litigation settlements  1,149   44   -   1,193 
Advertising cost adjustment  -   (1,353)  -   (1,353)
Stock option expense  -   -   6,259   6,259 
Long-term incentive compensation  -   -   901   901 
Adjusted EBITDA $113,167  $71,281  $(14,057) $170,391 
-31-

RECONCILIATION OF ADJUSTED NET INCOME 
(in thousands, except per share data)(unaudited) 
             
  Three Months Ended September 30,  Nine Months Ended September 30, 
  2017  2016  2017  2016 
Net income/(loss) as reported $35,437  $26,829  $43,625  $76,554 
                 
Add/(deduct) after-tax cost of:                
Excess tax benefits on stock compensation  (1,783)  -   (8,121)  - 
Stock option expense  1,064   897   4,892   3,958 
Long-term incentive compensation  699   406   1,911   570 
Expenses of OIG investigation  578   370   3,198   2,535 
Program closure expenses  (223)  -   675   - 
Medicare cap sequestration adjustment  -   141   65   141 
Potential litigation settlement  -   -   55,800   - 
Expenses related to litigation settlements  -   -   129   27 
Early retirement expenses  -   -   -   2,840 
Adjusted net income $35,772  $28,643  $102,174  $86,625 
                 
Diluted Earnings Per Share As Reported                
Net income/(loss) $2.13  $1.62  $2.60  $4.54 
Average number of shares outstanding  16,676   16,559   16,763   16,851 
                 
Adjusted Diluted Earnings Per Share                
Adjusted net income $2.15  $1.73  $6.10  $5.14 
Adjusted average number of shares outstanding  16,676   16,559   16,763   16,851 
-32-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES 
OPERATING STATISTICS FOR VITAS SEGMENT 
(unaudited) 
  Three Months Ended September 30,  Nine Months Ended Setpember 30, 
OPERATING STATISTICS 2017  2016  2017  2016 
Net revenue ($000)            
Homecare $236,565  $225,348  $693,359  $659,477 
Inpatient  22,516   23,850   68,439   73,856 
Continuous care  29,870   33,895   94,426   106,026 
Total before Medicare cap allowance $288,951  $283,093  $856,224  $839,359 
Medicare cap allowance  -   (228)  (247)  (228)
Total $288,951  $282,865  $855,977  $839,131 
Net revenue as a percent of total before Medicare cap allowances                
Homecare  81.9%  79.6%  81.0%  78.6%
Inpatient  7.8   8.4   8.0   8.8 
Continuous care  10.3   12.0   11.0   12.6 
Total before Medicare cap allowance  100.0   100.0   100.0   100.0 
Medicare cap allowance  -   (0.1)  -   - 
Total  100.0%  99.9%  100.0%  100.0%
Average daily census (days)                
Homecare  12,596   12,223   12,444   11,972 
Nursing home  3,254   3,077   3,148   3,028 
Routine homecare  15,850   15,300   15,592   15,000 
Inpatient  354   394   358   406 
Continuous care  448   507   475   530 
Total  16,652   16,201   16,425   15,936 
Total Admissions  16,000   16,157   49,874   49,205 
Total Discharges  15,726   15,690   49,074   48,403 
Average length of stay (days)  89.5   87.7   87.9   85.2 
Median length of stay (days)  16.0   16.0   16.0   16.0 
ADC by major diagnosis                
Cerebro  35.6%  32.9%  35.0%  32.2%
Neurological  18.9   20.7   19.4   21.3 
Cardio  16.6   17.1   16.6   17.3 
Cancer  14.4   15.5   14.8   15.3 
Respiratory  7.9   7.8   7.9   7.8 
Other  6.6   6.0   6.3   6.1 
Total  100.0%  100.0%  100.0%  100.0%
Admissions by major diagnosis                
Cerebro  22.0   21.2%  21.9%  20.9%
Neurological  10.0   11.0   10.5   11.0 
Cancer  31.5   33.3   30.8   31.9 
Cardio  14.9   14.4   15.1   15.3 
Respiratory  10.6   9.0   10.9   10.1 
Other  11.0   11.1   10.8   10.8 
Total  100.0%  100.0%  100.0%  100.0%
Direct patient care margins                
Routine homecare  52.4%  51.4%  52.2%  51.8%
Inpatient  3.4   (2.4)  4.4   2.7 
Continuous care  17.3   12.2   16.9   13.7 
Homecare margin drivers (dollars per patient day)                
Labor costs $56.48  $56.53  $57.20  $56.51 
Combined drug, HME and medical supplies  14.67   16.30   14.77   15.90 
Inpatient margin drivers (dollars per patient day)                
Labor costs $362.48  $360.35  $369.77  $346.61 
Continuous care margin drivers (dollars per patient day)                
Labor costs $579.31  $618.15  $584.82  $609.08 
Bad debt expense as a percent of revenues  1.1%  1.2%  1.1%  1.2%
Accounts receivable -- Days of revenue outstanding- excluding unapplied Medicare payments  34.6   38.4  n.a  n.a. 
Accounts receivable -- Days of revenue outstanding- including unapplied Medicare payments  19.9   20.7  n.a  n.a. 
-33-


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information


Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.


Item 3.    Quantitative and Qualitative Disclosures about Market Risk

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At September 30, 2017,March 31, 2023, the Company had $82.5$21.3 million of variable rate debt outstanding. For each $10 million dollars borrowed under the credit facility, an increase or decrease of 100 basis points (1% point)), increases or decreases the Company’s annual interest expense by $100,000.


The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.


Item 4. Controls and Procedures

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


PART II.    OTHER INFORMATION

Item 1.   Legal Proceedings


For information regarding the Company’s legal proceedings, see noteNote 10, Legal and Regulatory Matters, under Part I, Item I of this Quarterly Report on Form 10-Q.


Item 1A.    Risk Factors


There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.


-34-

-30-



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds


Item 2(c).  Purchases of Equity Securities by Issuer and Affiliated Purchasers


The following table shows the activity related to our share repurchase program for the first ninethree months of 2017:2023:

Total Number

Weighted Average

Cumulative Shares

Dollar Amount

of Shares

Price Paid Per

Repurchased Under

Remaining Under

Repurchased

Share

the Program

The Program

February 2011 Program 

January 1 through January 31, 2023

-

$

-

10,458,154 

$

87,867,735 

February 1 through February 28, 2023

-

-

10,458,154 

87,867,735 

March 1 through March 31, 2023

-

-

10,458,154 

$

87,867,735 

First Quarter Total

-

$

-

  Total Number  Weighted Average  Cumulative Shares  Dollar Amount 
  of Shares  Price Paid Per  Repurchased Under  Remaining Under 
  Repurchased  Share  the Program  The Program 
             
February 2011 Program
            
January 1 through January 31, 2017  -  $-   7,315,718  $50,173,009 
February 1 through February 28, 2017  104,358   178.39   7,420,076   31,556,555 
March 1 through March 31, 2017  195,642   182.20   7,615,718  $95,910,768 
                 
First Quarter Total  300,000  $180.87         
                 
April 1 through April 30, 2017  -  $-   7,615,718  $95,910,768 
May 1 through May 31, 2017  150,000   205.34   7,765,718   65,109,586 
June 1 through June 30, 2017  -   -   7,765,718  $65,109,586 
                 
Second Quarter Total  150,000  $205.34         
                 
July 1 through July 31, 2017  -  $-   7,765,718  $65,109,586 
August 1 through August 31, 2017  47,726   191.53   7,813,444   55,968,634 
September 1 through September 30, 2017  2,274   191.42   7,815,718  $55,533,344 
                 
Third Quarter Total  50,000  $191.52         
On March 13, 2017 our Board of Directors authorized an additional $100 million under the February 2011 Repurchase Program.

Item 3.    Defaults Upon Senior Securities


None.


Item 4.   Mine Safety Disclosures


None.


Item 5.    Other Information


None.



-35-

-31-



Item 6. Exhibits


Exhibit No.

Description

31.1

Exhibit No.

Description

31.1

Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.

31.2

Certification by David P. Williams pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.

31.3

Certification by Michael D. Witzeman pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.

32.1

Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification by David P. Williams pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.3

Certification by Michael D. Witzeman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.2002

101.INS

101 

XBRL Instance Document

The following materials from Chemed Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) The Condensed Consolidated Balance Sheet, (ii) The Condensed Consolidated Statement of Income, (iii) The Condensed Consolidated Statement of Cash Flows, (iv) The Condensed Statement of Equity, and (v) Notes to the Condensed Consolidated Financial Statements.

104

101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation Linkbase
101.DEFXBRL Taxonomy Extension Definition Linkbase
101.LABXBRL Taxonomy Extension Label Linkbase
101.PREXBRL Taxonomy Extension Presentation Linkbase

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in iXBRL and contained in Exhibit 101.


SIGNATURES

-32-



SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Chemed Corporation

(Registrant)

Chemed Corporation

(Registrant)

Dated:

October 27, 2017

By:

Dated:

April 28, 2023

By:

/s/ Kevin J. McNamara

Kevin J. McNamara

(President and Chief Executive Officer)

Dated:

Dated:

April 28, 2023

October 27, 2017

By:

By:

/s/ David P. Williams

David P. Williams

(Executive Vice President and Chief Financial Officer)

Dated:

Dated:

April 28, 2023

October 27, 2017

By:

By:

/s/ Michael D. Witzeman

Michael D. Witzeman

(Vice President and Controller)


-33-

-36-